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ABSTRACT 
 
Giant Cell arteritis (GCA) is a systemic inflammatory disease that affects arteries 
of medium- and large size.  Symptoms of GCA such as headache and fever 
usually promptly improve with treatment of glucocorticoids. Apart from advanced 
age, female sex and Northern-European descent, risk factors for GCA are 
unknown.  Most studies have found that life expectancy for patients with GCA is 
not reduced compared with the general population and studies on cardiovascular 
disease in GCA have provided conflicting results.  
Data for the studies of this thesis are drawn from the Reykjavik Study (RS) that is 
a general population-based cohort study with continuous surveillance for 
coronary heart disease and vital status. Subjects born in 1907–1934 and living in 
Reykjavik, Iceland or adjacent communities in 1966 were invited for study visit 
from 1967-1994. Information on cardiovascular risk factors were collected at 
study visit.  Diagnosis of GCA for this study was based on re-examination of all 
temporal arteries biopsies (TAB) from members of the RS cohort; however, 
information was also obtained from the original pathology report.   
   ix
Of 19,360 subjects included in the RS, 194 developed GCA during the follow-up 
period. Body mass index was inversely associated with the occurrence of GCA.  
Among men, but not women, hypertension was associated and smoking 
inversely associated with the occurrence of GCA.  Among women, but not men, 
GCA was associated with coronary heart disease.  Subjects with GCA had 
approximately 50% increase in mortality risk compared with the general 
population. Increase mortality was mainly observed among GCA patients based 
on the diagnosis of re-examination of TAB; however, no such an association was 
found if diagnosis of GCA was made based on the original pathology report. 
Those subjects were likely not clinically diagnosed with GCA, signaling that 
treatment for GCA might be beneficial with respect to mortality risk.  
  
   x
Table of Contents 
Title Page i 
Copyright Page ii 
Readers’ Approval Page iii 
Dedication iv 
Acknowledgments v 
Abstract viii 
Table of Contents x 
List of Tables xii 
List of Figures xv 
List of Abbreviations xvi 
 
General introduction 1 
 Giant Cell Arteritis 1 
 The Reykjavik Study 5 
 The Dungal repository of histopathological specimens 8 
 References 10 
 
Study A:  Cardiovascular Risk Factors and Incident Giant Cell Arteritis 16 
 Introduction 19 
 Methods 20 
 Results 28 
 Discussion 44 
   xi
 References 50 
 
Study B:  Giant Cell Arteritis and Incident Coronary Heart Disease 53 
 Introduction 55 
 Methods 57 
 Results 62 
 Discussion 74 
 References 78 
 
Study C: The Association of Giant Cell Arteritis and it´s Histopathology 
with All-cause and Cardiovascular Mortality 80 
 Introduction 83 
 Methods 85 
 Results 90 
 Discussion 100 
 References 104 
 
Appendix A: SAS macro for calculation of standardized incidence rate 
ratios 106 
Appendix B: SAS macro for calculation of seasonality estimator 114 
Bibliography 116 
Vita 125 
  
   xii
List of Tables 
 
Table A.1. Baseline characteristics of the study subjects 30
Table A.2.  Age stratified analysis of cardiovascular risk factors with 
having temporal artery biopsy done. 
33
Table A.3.  Age- and sex stratified incidence rate of GCA.   34
Table A.4.  Incident GCA stratified according to age, sex and 
cardiovascular risk factors. 
36
Table A.5.  Age-standardized- and CVD risk factor standardized- 
estimates of effects of cardiovascular risk factors on GCA. 
37
Table A.6.  Effect of cardiovascular risk factors on GCA. 38
Table A.7.  The association of smoking status with incident GCA 
stratified for decade of study visit to the RS. 
39
Table A.8. Age- and sex stratified incidence rate of GCA among those 
that came for a single study visit and those that came for repeated 
visits in the Reykjavik study  
41
Table A.9.  Association of risk factors with GCA according among those 
who came for a single vs. multiple study visits.  
42
Table A.10: Effect of cardiovascular risk factors on incidence GCA 
during the total follow-up time and after January 1st 1980 only.   
43
Table B.1. Baseline characteristics of the exposed and unexposed 
subjects.  
64
Table B.2. Age- and sex stratified incidence of CHD.  65
   xiii
Table B.3. Incidence rate of non-fatal coronary heart disease (MI, PCI 
and CABG) and sudden cardiac death. 
67
Table B.4. Incidence of CHD stratified according to cardiovascular risk 
factors.  
68
Table B.5. Association of giant cell arteritis with incident CHD with 
three different methods for standardization. 
70
Table B.6. Association of GCA with incident CHD with IRR and HR 
from different survival models in a matched cohort analysis.  
71
Table B.7. Association of GCA with incident CHD stratified according to 
results of original biopsy report. 
73
Table C1. Three sub-cohorts generated from the parent RS study 
cohort used for assessing mortality risks. 
86
Table C.2. Baseline characteristics of the exposed and unexposed 
subjects.  
91
Table C.3. Age- and sex stratified incidence of mortality  92
Table C.4. Age- and sex stratified incidence of cardiovascular mortality 
and non-cardiovascular mortality.  
94
Table C.5. Mortality risks early and late after diagnosis of GCA.  95
Table C.6. Baseline characteristics and primary histologic findings 
among subjects who did not undergo TAB, subjects with negative 
TABs, and subjects with positive TABs further stratified according to 
whether TAB was originally reported negative or positive.  
96
   xiv
Table C.7. The association of findings of temporal artery biopsies and 
histologic features on all-cause mortality and cardiovascular 
mortality. 
97
Table C.8. The association of levels of inflammatory intensity on 
mortality and cardiovascular mortality among subjects with GCA 
stratified according to whether the diagnosis of GCA was made by 
the original biopsy report.  
99
 
  
   xv
List of Figures 
Figure 1.  Timeline of events in the Reykjavik Study 8
Figure A.1.  Crude incidence rate of temporal artery biopsies and GCA  31
Figure A.2. Age-standardized incidence of temporal artery biopsies for 
different age groups at three secular periods  
32
Figure A.3. Cumulative incidence of GCA.   35
Figure A.4 Hypothetical causal structure between risk factors of GCA 48
  
 
  
   xvi
Abbreviations 
AGES Age Gene/Environment Study 
BMI Body mass index 
CABG Coronary artery bypass grafting 
CHD Coronary heart disease 
CI Confidence interval 
cRR crude risk ratio 
csHR cause-specific hazard ratio 
DAG Directed acyclic graph 
dL deciliter 
DM Diabetes mellitus 
ECG Electrocardiogram 
ESR Erythrocyte sedimentation rate 
GC Giant cell 
GCA Giant cell arteritis 
HR Hazard ratio 
HRQoL Health-related quality of life 
IHA Icelandic Heart Association 
IR Incidence rate 
IRR Incidence rate ratio 
IPEW Inverse probability of exposure weighting 
IPCW  Inverse Probability of Censoring Weighting 
mg milligram 
mm/hr millimeter per hour 
mmol/L  millimol per liter 
PCI Percutaneous coronary intervention 
   xvii
PMR Polymyalgia rheumatica 
PY Person-year 
RD Risk difference 
RS Reykjavik Study 
sdHR subdistribution hazard ratio 
SCORE  Systemic Coronary Risk Evaluation 
SF-36 Short form 36 
stdIRR Standardized incidence rate ratio 
TAB Temporal artery biopsy 
UK United Kingdom 
WHO World Health Organization 
   1
General Introduction 
Giant cell arteritis 
Giant cell arteritis (GCA) is systemic inflammatory disease of older adults 
involving large- and medium– sized arteries (1, 2). The disease has a tropism 
towards extra-cranial vessels but involvement of large vessels is well known (3-6) 
and vasculitis in multiple organs has been described (7-9). GCA was first 
described as vasculitis in 1937 by Horton and the term “temporal arteritis” 
proposed for the disease (10). Other names suggested for this disease include 
Horton’s disease and cranial arteritis. It is not known whether GCA is a relatively 
new disease in humans or an ancient disease that was merely undescribed until 
few decades ago. Potential hints of representation of GCA in ancient artwork and 
articles has been reviewed (11, 12) but is not conclusive.  
The incidence of GCA is highest in Northern European countries and populations 
of Northern-European descent with incidence rate (IR) over 20/100,000 person-
years over the age of 50 (13-15), but much lower in Southern European countries 
and elsewhere (16-19).  There is limited data on the cause of GCA. In a crude 
experiment(20), Horton injected samples of finely ground temporal artery into the 
scalp of 5 healthy volunteers who had no reaction to the foreign tissue.  He also 
injected a similar specimen alongside a forearm vein in a patient with GCA who 
was in disease remission. The patient developed fever, anemia and elevated 
erythrocyte sedimentation rate (ESR). From this set of experiments, Horton 
concluded that GCA was an autoimmune disease.  A few studies have reported a 
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cyclical pattern of the incidence of GCA with peaks in the incidence every 7 years 
(14, 18, 19).  That has sparked speculations and the hypothesis that GCA might 
have an infectious or other environmental cause. Recently, preliminary reports 
have described identification of a species of the bacteria Burkholderia in the 
temporal arteries of patients with GCA and that vasculitis can be induced in mice 
by injecting them with the organism (21). At present, these findings remain to be 
fully described and replicated. Few studies have explored the association of 
cardiovascular risk factors with the occurrence of GCA (22-24) 
Manifestations of GCA include constitutional symptoms resulting from systemic 
inflammation and ischemia in tissues served by an affected artery. GCA often 
has a fairly abrupt onset.  Symptoms include headache, scalp tenderness, jaw 
claudication and visual disturbances that can include double vision, monocular- 
and even bilateral blindness (25-27). In addition pain and stiffness in shoulders, 
hips, buttocks and lower back with pronounced morning stiffness are common in 
GCA (27). Those musculoskeletal symptoms are identical to symptoms of 
polymyalgia rheumatica (PMR). PMR and GCA also share pathologic 
mechanisms and by some investigators and clinicians, PMR is considered an 
incomplete form of GCA where vascular inflammation is not present or difficult to 
detect (28).  Inflammatory markers are usually elevated and ESR is often 
markedly raised (27). Prompt resolution of symptoms is usually observed with 
treatment; symptoms resistant to high dose glucocorticoids should lead to 
reevaluation of the diagnosis of GCA.  Data are scarce as to how GCA affects 
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health related quality of life (HRQoL). One study found no association of scores 
on the short form 36 (SF-36) with disease manifestations of the vasculitis and 
sub-scores appear comparable with those from the general population (29), but 
another study identified that domains of HRQoL that are important to patients 
with GCA are poorly covered by generic HRQoL instruments (30).   
Classification criteria for GCA have been developed (1) that are useful for 
discriminating between patients with GCA and patients with other systemic 
vasculitis.  These criteria, however, are not useful for discriminating between 
GCA from various common diseases (for example sinusitis) and therefore, have 
very limited utility for clinical practice. While some clinical symptoms are specific 
for GCA, it is recommended to confirm the diagnosis with a temporal artery 
biopsy (TAB) as management requires committing patients to high doses of 
glucocorticoids for substantial period of time. However, obtaining a TAB should 
not delay starting treatment (31). The histologic findings on TAB that are 
compatible with GCA are heterogeneous and no defined subtypes that are of 
clinical importance have been reliably described (32–34).  Giant cells (GC), from 
which the disease takes its name, are often seen. GC are formed by coalescence 
of inflammatory cells and are characteristic for the disease.  Giant cells are not 
uniquely seen in GCA; they may occur in many other inflammatory diseases.  
Glucocorticoids are the main treatment for GCA. Treatment with glucocorticoids 
is based on experience but not randomized controlled trials (RCT).  Treatment is 
usually started at 40 to 60mg of prednisone or prednisolone daily. The 
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glucocorticoids are then tapered slowly, over a period of at least 4 to 5 months, 
and often much longer.  Treatment with methotrexate (MTX) in addition to 
glucocorticoids has been shown to increase likelihood of successfully tapering 
glucocorticoids, reducing total dose of glucocorticoids and decreasing risk of 
disease relapse (35). Despite the available data on the utility of MTX for GCA, it 
is not universally accepted as a first-line treatment. It is possible that aspirin 
might prevent occurrence of visual complications (36, 37) and it is usually 
recommended (31).  After disease remission has been induced, at least 50% of 
patients experience a disease relapse (38–40). Disease relapses most often 
manifest themselves as headache, constitutional symptoms and elevated 
inflammatory markers, but serious ischemic events such as vision loss can occur 
(38). 
While GCA affects large vital arteries and being diagnosed with the disease is 
associated with prolonged exposure of high doses of glucocorticoids, most (41–
44) but not all  (45, 46) studies have found no shortened lifespan among patients 
with GCA compared with the general population. As the disease is always 
treated with glucocorticoids, data are unavailable as how treatment of disease 
affects mortality risk. Despite well-documented involvement of multiple vascular 
beds in GCA, data are conflicting as to how GCA is associated with important 
cardiovascular events (47–49).   
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The objectives of the projects included in this thesis are to study the association 
of cardiovascular risk factors with incident GCA and to measure the effect of 
GCA on risk for coronary heart disease and mortality in the general population.  
 
The Reykjavik Study 
History  
The Reykjavik Study is a general population-based cohort study run by the 
Icelandic Heart Association (IHA) (50). The IHA was founded in 1964 with the 
mission to fight cardiovascular disease and study its occurrence and 
complications in the Icelandic population.  In 1967, the Reykjavik Study was 
initiated in response to this stated objective of the IHA.  Initial funding was 
obtained from successful fundraising among the Icelandic general public allowing 
IHA to build a research facility and support a young physician to study 
epidemiology at London School of Hygiene and Tropical Medicine.  The World 
Health Organization (WHO) European regional office in Copenhagen, Denmark 
provided operational guidance for initiation of the study.  The research facilities 
were equipped with the state-of-the-art devices of the time, including the nation’s 
first automatic chemical analyzer for blood test, x-ray machines, respiratory 
analyzer for pulmonary function tests, and devices for conducting exercise 
tolerance tests. Each day, the research facility could invite about 30 participants 
for a study visit.  
The first research subject came to the RS in 1967 and the last study visit was in 
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1997. Over the 30-year period, data collection followed the same research 
protocol.  Since 1981 IHA has participated in a multinational study (MONICA) 
under the oversight of WHO for standardized detection of myocardial infarctions 
among all Icelanders.  
The IHA has collaborated extensively both internationally and with the community 
of physicians and epidemiology researchers in Iceland. In addition to data 
collected on behalf of RS, the IHA has invited investigators to collect additional 
data on research subjects from other sources (as is done in the projects of this 
thesis) and therefore, many data elements are available that are outside of the 
scope of cardiovascular disease.  Several other population studies have been 
conducted that build on the RS, such as the RS offspring study and The Age-
Gene Environment Study (AGES) (51).  Data originating from the RS have been 
a major asset for epidemiological and clinical studies in Iceland. To date over 500 
scientific papers and multiple PhD thesis have resulted from RS data.   
 
Study population. 
All men born between 1907 and 1934 and women born between 1908 and 1935 
and living in Reykjavik, Iceland on December 1st, 1967 (n=30,795) were invited 
for participation in RS.  Of them, about 70% enrolled in the study (N=19,360: 
10,050 women and 9,310 men).  The study participants were divided into six 
groups (A-F) based on their birth date within a month.  Examination took place in 
six stages from 1967–1996 (stage I: 1967–1969, stage II: 1970–1972, stage III: 
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1974–1979, stage IV: 1979–1984, stage V: 1985–1991 and stage VI: 1991–
1996).  Groups were examined at one examination stage except one group (B), 
which was designed for longitudinal follow-up and was examined in all six stages.  
Men and women were examined in separate years for more efficient clinic 
operation.  At the last stage of the study (stage VI), only subjects who had 
reached 70 years of age were invited. Timeline of events are depicted in Figure 
1.  Cardiovascular disease is the primary focus of the RS, and the effect of 
cardiovascular risk factors (hypertension, smoking, diabetes mellitus and serum 
cholesterol) on cardiovascular events have been found to be almost identical to 
data originating from 12 European cohorts compiled as part of the Systemic 
Coronary Risk Evaluation project (SCORE) (52).  Loss to follow-up and vital 
status are only due to emigration, which during the study’s follow-up time has 
been low, with only 0.5% of the RS cohort having emigrated from Iceland (53). 
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Figure 1.  Timeline of events in the Reykjavik Study (RS: Reykjavik Study, 
CHD: Coronary heart disease) 
 
The Dungal repository of histopathological specimens 
The Dungal repository was initiated in 1934 by Niels Dungal, former professor of 
pathology and chancellor of University of Iceland.  Under Dr. Dungal’s oversight 
all histopathological specimens obtained among Icelanders for clinical purposes 
were collected for permanent storage. To date the three pathology laboratories in 
Iceland continue to submit their specimens to repository, which currently has 
over 500,000 specimens. The specimens are stored in the original blocks of 
paraffin wax, but not on the glass slides, allowing for creation of new pathologic 
slides if quality of existing slides deteriorates or if new staining techniques 
emerge. . This nationwide collection naturally includes all TABs obtained in 
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Iceland during the study period of the RS and allowed for re-staining of old TAB 
(where the original staining had fainted), for the purpose of studies included in 
this thesis.  
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Abstract 
Objective:  To assess the strength of the effect of cardiovascular risk factors on 
incidence of GCA within a longitudinal cohort study where detailed information on 
cardiovascular risk factors has been collected. 
Methods: Data from the Reykjavik Study (RS), a population-based, prospective 
cohort study with a primary focus on cardiovascular disease, were used.  All 
persons born in 1907–1935 who were living in Reykjavik, Iceland or in adjacent 
communities on December 1, 1967 were invited to participate.  Subjects came for 
a study visit in 1967–1996 and information on cardiovascular risk factors: 
smoking habits, blood pressure, diabetes, body mass index, and serum 
cholesterol was obtained.  All temporal artery biopsies (TABs) obtained on 
members of the RS cohort were identified in all three pathology laboratories in 
Iceland during the period 1961–2009.  All TABs were re-examined in a 
protocolled and blinded fashion by a single pathologist with expertise in vascular 
pathology.  Incidence was calculated for exposed and unexposed subjects and 
incidence rate ratios (IRR) presented with 95% confidence intervals.   
Results:  For this analysis, data from 19,241 subjects who were followed for a 
median 23.1 (IQR: 17.6–29.4) years after the age of 50, were used.  Over 
444,126 person-years of follow-up, 194 subjects had developed GCA, 
corresponding to an incidence rate of 43.6 (95% CI: 37.8–50.2) per 100,000 
person-years.  Woman had increased incidence of GCA compared with men, 
IRR= 1.93 (95% CI: 1.42–2.62).  Among cardiovascular risk factors, high BMI 
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was inversely associated with GCA, with those of BMI>25kg/m2 having IRR= 
0.66 (95% CI: 0.50–0.88) and smoking was inversely associated with GCA 
among men, but not women,  
Conclusion: This study shows a very high incidence of GCA in Iceland, greater 
than previously reported.  A high BMI is protective for the occurrence of GCA and 
smoking may be protective for the occurrence of the disease among men. 
  
   19
Introduction 
Apart from advanced age, female sex, and Northern European descent, risk 
factors for GCA are not well defined.  There is limited information on the 
association between traditional cardiovascular risk factors and GCA.  Twenty 
years ago, the question about the relationship between GCA and common 
vascular disease was raised by a description of an association of GCA with 
smoking, peripheral arterial disease, and angina (1).  More recent studies have 
described an association between smoking (2, 3) and GCA and an inverse 
association of serum cholesterol (2) and body mass index (BMI) with GCA.  
Limitations of previous studies include retrospective designs with reliance on self-
report of risk factors obtained after the outcome of interest (GCA) has occurred. 
Few studies have reported a cyclical pattern in the incidence of GCA with peaks 
occurring every 5–10 years (4–6), while others have not (7, 8).  
 
The objective of this study was to assess the strength of the effect of 
cardiovascular risk factors on incidence GCA within a longitudinal cohort study 
where detailed information on cardiovascular risk factors was obtained, and to 
explore if incidence follows a cyclical pattern similar to what has been described 
in other cohort studies.  
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Methods 
Study Design 
To examine the effect of cardiovascular risk factors on incident GCA, a cohort 
study design was used.  Ethical approvals were obtained from Boston Medical 
Center Institutional Review Board and the National Bioethics Committee in 
Iceland.   
 
Study population 
The Reykjavik Study (RS) has been described in a detail previously (see page 4). 
Briefly, persons, who were born in 1907–1935 and living in Reykjavik or in 
adjacent communities, Iceland on December 1, 1967, were invited to participate.  
Subjects came for a study visit in 1967–1996 and information on cardiovascular 
risk factors was obtained.  Individuals who died before the age of 50 (at which 
age, follow-up for this study started) and subjects with GCA at baseline were 
excluded from this analysis.  
Baseline assessment 
Baseline data was obtained from all members of the RS cohort in a standardized 
fashion during the whole study period.  The examination was carried out during 
two separate visits scheduled approximately 1 week apart.  The former visit 
included a blood draw after an overnight fasting and anthropometric measures 
including height and weight.  During the second visit, a physical examination was 
performed.  The following baseline data used in studies of this thesis is listed 
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below: 
 
1.  Hypertension  
Blood pressure was measured at both visits, in a supine position after 5 minutes 
of rest and was recorded to the nearest 2mmHg; a mercury sphygmomanometer 
(Erka-meter wall model; Richard Kallmeyer Nachforschung, Badtölz, Germany) 
was used.  A mean value of two blood pressure measurements was used for 
analysis.  Hypertension was defined as systolic blood pressure ≥140 mmHg or 
medication use to lower blood pressure. 
2.  Smoking 
Information on smoking was obtained through questionnaire and smoking status 
defined as never, former or current smoker.  
3.  Diabetes Mellitus (DM) 
DM was defined as fasting serum glucose ≥110 mg/dL or use of medications to 
treat diabetes mellitus. 
4.  Total cholesterol 
Total cholesterol was measured in serum after overnight fasting.  To explore 
potential non-linear association of total cholesterol with GCA, associations of 
serum cholesterol quartiles with GCA were examined in tabular analysis but in 
regression analyses total cholesterol was entered as a continuous variable. 
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5.  Body mass index (BMI) 
BMI calculated as weight in kg/(height in meters)2 was used to define undeweight 
(BMI<18.5), normal weight (18.5≤BMI<25) overweight (25≤BMI<30) and obese 
(BMI>30).  
6.  Inflammation 
The effect of systemic inflammatory response as measured by erythrocyte 
sedimentation rate (ESR), obtained from all members of RS cohort during a 
study visit.  It was studied after grouping into three categories: 0 to 10, 11 to 20, 
and 21 and higher; it was also included  as a continuous linear predictor in a 
regression analysis. 
 
Follow-up and outcome assessment 
All subjects were followed from the time of study visit or the age of 50, whichever 
occurred later until the time of death, December 31st 2008, or the outcome of 
GCA, whichever occurred first.  The outcome of GCA was defined as a 
diagnostic temporal artery biopsy at i) Department of Pathology, University of 
Iceland; ii) a private pathology laboratory in Reykjavik; or iii) the Pathology 
Laboratory at Akureyri Hospital.  Together, these laboratories have computerized 
records back to 1960 and serve the whole Icelandic population.  Information was 
linked to the RS through the Social Security Number.  All temporal artery 
biopsies obtained from members of the RS cohort for clinical purpose were re-
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examined according to a predefined protocol by a single pathologist with 
expertise in pathology of the vasculitides.  In this analysis, we defined a subject 
to have diagnosis of GCA if his/her biopsy showed infiltration of inflammatory 
cells to the vessel wall with the exception of very scant inflammatory cells in the 
outermost layer (tunica adventitia) of the vessel wall in an otherwise normal 
vessel.     
Statistical Analysis 
Secular incidence of GCA and TAB was calculated as number of events each 
calendar year divided by person-years contributed by members of the RS cohort 
that year. RS is a fixed cohort with all its members born in a 28 year period, 
between 1907 and 1935 but some subjects contributed longer follow-up time, up 
to 41 years (from 1967–2008) In this situation there is not enough age-overlap 
between early and later calendar times to fully assess any secular incidence 
trend that is standardized according to age; at the beginning of the study period 
(1967), the oldest subjects are younger than the youngest subjects in 2008. 
Therefore, age standardization was done in three periods to evaluate for secular 
changes in occurrence of temporal artery biopsies. 
To assess for if secular incidence of GCA in the RS cohort followed a cyclical 
pattern with peaks, a sine curve of cycle-length 7 years was fit and the seasonal 
intensity estimator calculated as previously described (9): The total period during 
which incident GCA occurred among member of the cohort (1980–2008) was 
divided to four 7 year cycles (1980–1986, 1987–1993, 1994–2000 and 2001–
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2007) (subjects with GCA in 2008 were omitted from this analysis). Then total 
number of subjects with GCA in the first sector of the cycle, N1 was the sum of 
subjects with GCA in the years 1980, 1987,1994 and 2001, the number of 
subjects for the second sector, N2, was the number of subjects with GCA in the 
years 1981, 1988, 1995 and 2002 etc. The seasonal estimator, R which is the 
ratio between the peaks and troughs in the incidence of the fitted sine curve, was 
calculated as    
 
Where α is the hemi amplitude of the fitted sine curve calculated as  
 
Where k is set to 7 and N is the total number of subjects with GCA during the 
period under study and D calculated as  
 
Where θi ൌ 2πi/k  The measure of cyclical occurrence with peak every 7 years 
is expressed as the seasonal estimator R with 95% CI. The CIs for this estimate 
are calculated in usual fashion where the standard error for ln(R) is: 
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Where VAR(α) is 2/N  
For evaluation of the effect of cardiovascular risk factors on the occurrence of 
GCA, the incidence rate (IR) for subjects was calculated using the number of 
incident GCA during the person-time contributed by the exposed with each 
cardiovascular risk factor.  The IR was calculated among the exposed and 
unexposed subjects and effect of each exposure is expressed as an incidence 
rate ratio (IRR) with 95% confidence intervals (CI).  The effect of each 
cardiovascular risk factor was explored in the strata of sex and age categorized 
as younger (50 to 70 years) and older than 70 years.  To adjust for potential 
confounding, standardized IRR were calculated using person-time contributed by 
the exposed group as weights.  In the light of scarce previous data and therefore 
limited insight to the potential causal pathways from cardiovascular risk factors to 
GCA, standardized effect estimates were calculated across strata of all the other 
cardiovascular risk factors.  To explore the magnitude of confounding, relative 
risk due to confounding was calculated as IRRSTD/IRRCRUDE.  As we found 
substantial effect measure modification by sex, effects of all cardiovascular risk 
factors on incident GCA are reported separately for men and women.  
In addition, a Cox proportional hazards regression was used to examine the 
association between each risk factor and risk of GCA.  As age is very strong risk 
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factor for GCA, we chose subjects’ age as the time-scale for the regression 
analysis; age was also included as an independent variable (10).  For risk factors 
that appeared to be of particular interest (smoking), survival curves adjusted for 
other risk factors with inverse probability weights were constructed (11). 
As cardiovascular risk factors were obtained at a single time-point, often many 
years before GCA, cardiovascular risk factors might have changed over time.  To 
evaluate for the effect for changing risk factors in this cohort with respect to GCA 
risk, analysis with time-varying predictors was done on the subset that came in 
for repeated study visits and compared with those that only came for one visit.  
Effects of cardiovascular risk factors were also calculated stratified for the period 
of their study visit (1970 and earlier, 1971–1980 and after 1980). As we found 
that TABs were exceedingly rarely performed on members of the RS cohort 
before 1980, in a supplemental analysis we explored the effect of cardiovascular 
risk factors on incident GCA using only person-time contributed after January 1st 
1980.  
In the survival analysis there are two types of censoring events: i) censoring at 
the time of death and ii) administrative censoring at the end of study follow-up.  
The assumption of uninformative censoring has to be made for the analyses of 
time to GCA.  If this assumption is not met, for example if cardiovascular risk 
factors are truly risk factors for mortality but not GCA, that will adversely affect 
the estimate on the cause-specific hazard ratio (csHR) of cardiovascular risk 
factors on GCA by preferentially removing exposed individuals from the risk set.  
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Therefore, the true risk from cardiovascular risk factors on GCA is both a function 
of csHR for the event of interest and the competing event (death)(12).  In an 
attempt to measure the effect of cardiovascular risk factors on GCA accounting 
for the competing event (death), the subdistribution hazard ratio (sdHR) was 
calculated according to the Fine and Gray method (6).  Using that method, both 
subjects that remain at risk for GCA and those that have died at time T are 
retained in the risk set (every subject fulfilling the criteria (Y≠GCA or Y=death 
│time<T). For calculations of the values for the covariates in the model, β, that 
best fit the data (maximal likelihood calculations (score equations)), a weighted 
score function is used. Weights for all subjects in the risk set at each failure time, 
T, are calculated from inverse probability of censoring weighting (IPCW) using 
the Kaplan-Meier estimate at that time.  
 
SAS 9.2 (SAS institute Cary, NC) was used for all calculations, a SAS macro 
(appendix A) was developed for calculations of standardized rate ratios. The 
macro was developed based on (and tested for errors against) Episheet (13) for 
calculations of standardized rate ratios.  A SAS macro (11) for graphically 
depicting adjusted survival curves inverse probability weights was used with 
minor modifications.  A SAS macro was developed for calculating the seasonality 
estimator (appendix B) The statistical package cmprsk in R was used for 
calculations subdistribution hazards ratios according to the Fine and Gray 
method (12).    
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Results 
Study population  
There were 19,360 subjects that participated in the Reykjavik Study and came for 
a study visit from October 26th 1967 to April 23rd 1996, about 70% of those 
originally invited.  Twelve subjects had a temporal artery biopsy diagnostic of 
GCA before their RS study visit and are excluded from the analysis.  One 
hundred and seven subjects died before the age of 50 and therefore contributed 
no person-time to this analysis.  Therefore, 19,241 subjects are included in this 
analysis.   
Baseline characteristics 
Of the 19,241 subjects included, there were 10,006 women and 9,235 men.  The 
baseline characteristics at the first visit to the RS (or last visit before the age of 
50 when subjects started to contribute follow-up time) are shown in Table A.1.  
There was very high prevalence of tobacco smoking in this cohort.  Only 21% of 
the men and 44% of the women were never smokers.  Less than 5% study 
subjects had diabetes mellitus at baseline.  There were considerable secular 
changes in smoking habits during the study visit period: 62% of men and 47% of 
women who came for their first study visit between 1967–1970 were current 
smokers, whereas 41% of men and 34% of women who came for their first study 
visit after 1980 were current smokers.  There was clear trend for increase in BMI 
and prevalence of diabetes mellitus.  However, as very few subjects had DM, no 
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meaningful estimates of the association of DM with incident GCA could be 
obtained. Other risk factors were more stable during follow-up.   
Temporal artery biopsies 
Of the 19,241 subjects, 703 underwent TAB.  TABs were rarely performed on 
members of this cohort until about 1980, but then there was an abrupt increase.  
Although maximal numbers of biopsies were not obtained from members of this 
cohort until 1990 that was probably appropriate given the age distribution of the 
cohort.  Crude incidence of temporal artery biopsies in the RS cohort is shown in 
the Figure A.1 and age-standardized incidence in Figure A.2. 
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 Women 
(N=10,006 
PY=238,128) 
Men 
(N=9,235 
PY=205,999) 
Age    
50 to 60 years 56,267 (24%) 56,036 (27%) 
60 to 70 years 81,095 (34%) 72,552 (35%) 
70 to 80 years 69,807 (29%) 57,157 (28%) 
after 80 years 30,958 (13%) 20,254 (10%) 
Hypertension  86,280 (36%) 82,439 (40%) 
Smoking    
never 110,609 (46%) 48,078 (23%) 
former 37,712 (16%) 50,868 (25%) 
current smoking 89,807 (38%) 107,024 (52%) 
Total Cholesterol 
(mmol/L) 
  
<5.7 51,849 (22%) 51,849 (22%) 
5.7–6.3 54,791 (23%) 54,791(23%) 
6.4–7.1 62,345 (26%) 62,345 (26%) 
>7.2 68,857 (29%) 68,857(29%) 
DM 6,261   (3%) 6,951  (3%) 
BMI   
underweight (<18.5) 4,494   (2%) 1,379   (1%) 
normal weight (18.5–24.9) 124,511 (53%) 86,237 (42%) 
overweight (25.0-24.9) 81,240 (34%) 97,885 (48%) 
obese (≥30) 26,481 (11%) 19,903 (10%) 
ESR (mm/hr)   
0–10 135,895 (57%) 168,653 (82%) 
11–20 66,659 (28%) 28,146 (14%) 
>21 34,037 (14%) 8,514   (4%) 
Table A.1. Baseline characteristics of the study subjects. Variables 
expressed as number of person-years (percentage) in each strata (N=number 
of subjects, PY=person-years, L=liter, DM=diabetes mellitus, BMI=body mass 
index, ESR=erythrocyte sedimentation rate, mm=millimeter, hr=hour).  
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Figure A.1.  Crude incidence rate of temporal artery biopsies and GCA for people 
age 50 or greater.  The figure shows the secular crude incidence of GCA and first 
temporal artery biopsy among members of the RS cohort.  On the x-axis is calendar time 
in years and on the y-axis the incidence per 100,000 person-years above the age of 50.  
The numbers below the x-axis is number of subjects at the age 65-80 (the age period at 
which 75% of patients with GCA were, when diagnosed with GCA) that are contributing 
person-time (TAB=temporal artery biopsy, GCA=Giant cell arteritis, RS=Reykjavik 
Study).   
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Figure A.2. Age-standardized incidence of temporal artery biopsies for different 
age groups at three secular periods:  A. Incidence of biopsies among 50–65 year old 
subjects of RS in 1970 to 1985, age-standardized to the 1978 population. B. Incidence 
of biopsies among 60–75 year old subjects of RS in 1980 to 1995, age-standardized to 
the 1988 population, and C. Incidence of temporal artery biopsies in 1993 to 2008 
standardized to the 2000 population.   
 
Elevated ESR was associated with having a TAB performed both among men 
and women (Table A.2). Among women, ever smoking was modestly associated 
with TAB and in men, HTN was associated with TAB.  
 
Incidence of GCA 
The 19,241 study subjects were followed for a mean 24.3 years after they 
achieved the age of 50 (IQR: 17.6–29.8).  During 444,126 person-years of the 
follow-up period, 194 subjects had developed GCA, representing an incidence 
rate of 43.6 (95% CI: 37.8–50.2) per 100,000 person-years after the age of 50.   
   33
 Women 
IRR 
Men 
IRR 
Hypertension 1.10(0.92-1.32) 1.52(1.16-2.01) 
Ever smoking 1.27(1.06-1.51) 0.89(0.65-1.21) 
Cholesterol (mmol/L)   
<5.7 1 (ref) 1 (ref) 
5.7-6.3 0.96(0.73-1.27) 1.28(0.86-1.91) 
6.4-7.1 1.19(0.92-1.55) 1.39(0.94-2.06) 
>7.2 1.04(0.81-1.35) 1.23(0.80-1.88) 
BMI   
underweight (<18.5) 0.51(0.21-1.24) 0.96(0.13-6.91) 
normal weight (18.5-24.9) 1 (ref) 1 (ref) 
overweight (25.0-24.9) 0.94(0.78-1.14) 0.99(0.74-1.32) 
obese (≥30) 0.76(0.56-1.04) 0.85(0.50-1.42) 
ESR (mm/hr)   
0 to 10 1 (ref) 1 (ref) 
11 to 20 1.46(1.18-1.79) 2.21(1.60-3.06) 
21 and higher 2.41(1.94-3.00) 3.03(1.89-4.85) 
Table A.2.  Age standardized analysis of cardiovascular risk factors with having 
temporal artery biopsy done.  (IRR=incidence rate ratio, L=liter, BMI=body mass index, 
IRR=incidence rate ratio, ESR=Erythrocyte sedimentation rate, mm=millimeter, hr=hour) 
 
The IR fluctuated somewhat between calendar years (Figure A.2) and analysis 
was consistent with that cyclical occurrence in GCA following a sine curve with 
seasonality estimator of R=2.07 (95% CI 1.31–3.26). The mean age of diagnosis 
of GCA was 73.4 years (range: 56.1–90.0 years) and 71% subjects were 
between 65 and 80 years of age when they had a TAB diagnostic of GCA.  
Women had higher risk of GCA than men, especially among those less than 80 
years (Table A.3). 
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 GCA PY IR 
Women  
50 to 60 4 56,267 7.1
60 to 70  39 81,095 48.1
70 to 80  74 69,807 106
over 80 19 30,958 61.4
Men  
50 to 60 1 56,036 1.8
60 to 70  15 72,552 20.7
70 to 80  25 57,157 43.7
over 80 17 20,254 83.9
Both 
sexes  
50 to 60 5 112304 4.5
60 to 70  54 153646 35.1
70 to 80  99 126963 78.0
over 80 36 51213 70.3
 
Table A.3.  Age- and sex- specific incidence rate of GCA.  Incidence rate is 
presented as events/100,000 person-years (GCA= Giant cell arteritis, PY= person-years, 
IR=incidence rate).   
 
Association of cardiovascular risk factors with incident GCA 
Several cardiovascular risk factors were associated with incident GCA.  The 
effect of cardiovascular risk factors stratified according to age and sex is 
presented in Table A.4 and standardized effect estimates in Table A.5.  There 
was an inverse association between tobacco smoking and GCA among men. 
Compared with never smokers, IRR for GCA for ever smokers was 0.51 (95% CI: 
0.30–0.87).  However, such an association was not observed among women. 
The corresponding IRR was 1.12 (95% CI: 0.80–1.57).  BMI was inversely 
associated with GCA, especially among women. Hypertension was strongly 
associated with risk of GCA among men over 70 years of age (IRR= 3.04, 95% 
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CI: 1.58–5.86), but such an effect was not observed in the other strata of age and 
sex.  Almost identical results were obtained in a Cox proportional hazards 
regression analysis (Table A.6).  Cumulative incidence plots for of smoking 
among men and women adjusted for other risk factors are shown in Figure A.3.   
As there were secular changes in smoking habits during the conductance of the 
RS, we examined the effect of smoking in strata of calendar-period of study visit.  
The association of smoking on incident GCA was modified by the decade of 
study visit, especially among women.  Among women that came for their study 
visit before 1970, smoking was inversely associated with GCA, but among those 
that came after 1980, smoking was positively associated with GCA (Table A.7).  
There was less effect-measure modification observed with smoking in men by 
time of study visit.  
 
Figure A.3. Cumulative incidence of GCA.  Cumulative GCA-incidence curves for 
ever-smokers vs. never smokers among women and men in the RS cohort adjusted for 
HTN, BMI and cholesterol 
   36
 
Table A.4.  Incident GCA stratified according to age, sex and cardiovascular risk 
factors. Pearson-years are expressed in thousands of years (L=liter, BMI=body mass 
index, PY=Pearson-years IR=incidence rate, IRR=incidence rate ratio, ESR=Erythrocyte 
sedimentation rate) 
 Age 50 to 70 After  age 70 
 GCA PY IR IRR GCA PY IR IRR 
WOMEN         
Hypertension         
No  30 93.3 32.2 1 (ref) 58 58.5 99.1 1 (ref) 
Yes 13 44.0 29.5 0.92 (0.48-1.76) 35 42.2 82.9 0.84 (0.55-1.27)
Smoking      
Never 17 60.5 28.1 1 (ref) 44 50.0 87.9 1 (ref) 
Ever 26 76.7 33.9 1.21 (0.65-2.22) 49 50.7 96.6 1.1 (0.73-1.65) 
Cholesterol      
<6.3  mmol/L 19 66.4 28.6 1 (ref) 39 40.2 96.9 1 (ref) 
 ≥6.3  mmol/L 24 70.8 33.9 1.19 (0.65-2.16) 54 60.4 89.4 0.92 (0.61-1.39)
BMI*      
<25 24 77.0 31.2 1 (ref) 61 52.0 117 1 (ref) 
 ≥25 17 59.7 28.5 0.91 (0.49-1.7) 30 48.0 62.5 0.53 (0.34-0.82)
ESR**      
≤20 mm/hour 34 117 29 1 (ref) 72 85.3 84.5 1 (ref) 
>20 mm/hour 9 19.3 46.7 1.61 (0.77-3.36) 20 14.8 135 1.60 (0.98-2.63)
MEN      
Hypertension      
No 11 78.9 13.9 1 (ref) 13 44.7 29.1 1 (ref) 
Yes 5 49.7 10.1 0.73 (0.25-2.09) 29 32.7 88.6 3.04 (1.58-5.86)
Smoking      
Never 7 28.2 24.8 1 (ref) 16 19.9 80.6 1 (ref) 
Ever 9 100 9 0.36 (0.14-0.97) 26 57.5 45.2 0.56 (0.30-1.05)
Cholesterol      
<6.3  mmol/L 9 66.7 13.5 1 (ref) 20 40.5 49.4 1 (ref) 
 ≥6.3  mmol/L 7 61.6 11.4 0.84 (0.31-2.27) 22 36.7 59.9 1.21 (0.66-2.22)
BMI      
<25 8 54.8 14.6 1 (ref) 18 32.7 55 1 (ref) 
 ≥25 8 73.4 10.9 0.75 (0.28-1.99) 24 44.4 54 0.98 (0.53-1.81)
ESR      
≤20 mm/hour 15 123 12.2 1 (ref) 42 74.1 56.7 1 (ref) 
>20 mm/hour 1 5.5 18.2 1.49 (0.2-11.29) 0 3.00 0 -- 
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Table A.5.  Age-standardized- and CVD risk factor standardized- estimates of 
effects of cardiovascular risk factors on GCA.  Standardized incidence rate ratios are 
expressed with 95% confidence intervals.  Relative risk due to confounding by 
cardiovascular risk factors is expressed with cRR (IRR/stdIRR). (IRR=incidence rate 
ratio, CVD = cardiovascular disease, cRR=Relative risk due to confounding, BMI=body 
mass index, ESR=erythrocyte sedimentation rate) 
*Age standardization was done in 4 strata i) 50 to 60 year, ii) 61 to 70 years, iii) 71 to 80 
years and iv) after 80 years.  
**CVD Risk factor standardization was performed by calculating stratum specific 
incidence rate according to Hypertension, ever smoking, cholesterol (quartiles), BMI in 4 
categories (listed in table) and ESR in 3 categories (listed in table) 
***No outcome events occurred in the strata.  
 Women Men 
 
Age 
standardized 
IRR 
CVD risk 
factors 
standardized 
IRR cRR 
Age 
standardized 
IRR 
CVD risk 
factors 
standardized 
IRR cRR
HTN 0.88(0.61-1.25) 0.94(0.62-1.43) 0.94 2.00(1.18-3.37) 1.85(0.99-3.45) 1.08
Ever 
smoking 1.12(0.80-1.57) 0.99(0.69-1.41) 1.13 0.51(0.30-0.87) 0.47(0.27-0.81) 1.09
Cholesterol 
(mmol/L)       
<5.7 1 (ref) 1 (ref)  1 (ref) 1 (ref)  
5.7-6.3 0.96(0.58-1.61) 0.97(0.57-1.66) 0.99 0.89(0.43-1.84) 0.84(0.39-1.81) 1.06
6.4-7.1 1.06(0.65-1.72) 0.99(0.59-1.66) 1.07 1.14(0.58-2.27) 1.04(0.52-2.07) 1.10
>7.2 0.89(0.54-1.45) 0.82(0.47-1.43) 1.09 0.88(0.40-1.92) 1.01(0.45-2.25) 0.87
BMI       
<18.5 *** ***  *** ***  
18.5-24.9 1 (ref) 1 (ref)  1 (ref) 1 (ref)  
25.0-24.9 0.70(0.48-1.02) 0.75(0.51-1.12) 0.93 0.90(0.52-1.54) 0.76(0.44-1.31) 1.18
≥30 0.31(0.14-0.71) 0.31(0.13-0.74) 1.00 0.85(0.33-2.22) 0.86(0.29-2.53) 0.99
ESR 
(mm/hr)       
0-10 1 (ref) 1 (ref)  1 (ref) 1 (ref)  
11-20 0.99(0.66-1.48) 0.99(0.64-1.53) 1.00 1.44(0.76-2.73) 1.43(0.74-2.74) 1.00
>20 1.61(1.04-2.48) 1.75(1.04-2.96) 0.92 0.42(0.06-3.03) 0.22(0.03-1.62) 1.91
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 Women Men 
 HR SubHR HR SubHR 
Hypertension 0.89 (0.61-1.27) 0.89 (0.62-1.27) 1.92 (1.13-3.27) 1.77 (1.05-2.98) 
Ever smoking 1.12 (0.80-1.57) 0.98 (0.70-1.38) 0.51 (0.30-0.86) 0.43 (0.25-0.73) 
Cholesterol  
(mmol/L) 
    
 <5.7 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
  5.7-6.3 0.96 (0.57-1.61) 1.03 (0.61-1.72) 0.90 (0.43-1.85) 0.92 (0.44-1.91) 
  6.4-7.1 1.07 (0.65-1.74) 1.16 (0.71-1.89) 1.16 (0.58-2.30) 1.18 (0.58-2.36) 
  >7.2 0.93 (0.57-1.52) 1.03 (0.63-1.68) 0.90 (0.41-1.96) 0.89 (0.41-1.93) 
BMI     
<18.5  --  -- 
18.5-24.9 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
25.0-24.9 0.72(0.49-1.04) 0.74 (0.51-1.07) 0.89 (0.52-1.53) 0.90 (0.53-1.55) 
≥30 0.32 (0.14-0.74) 0.32 (0.14-0.72) 0.84 (0.33-2.21) 0.75 (0.29-1.97) 
ESR     
0-10 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
11-20 0.99 (0.66-1.48) 0.98 (0.65-1.47) 1.50 (0.79-2.84) 1.34 (0.72-2.50) 
>20 1.62 (1.05-2.49) 1.47 (0.95-2.26) 0.44 (0.06-3.17) 0.30 (0.04-2.23) 
 
Table A.6.  Effect of cardiovascular risk factors on GCA.   Estimates of effects are 
expressed with hazards ratios with 95% confidence intervals from Cox proportional 
hazards regression and subdistribution hazards ratio accounting for the competing event 
of mortality adjusted for hypertension, ever smoking, cholesterol and BMI (BMI=body 
mass index, ESR=erythrocyte sedimentations rate).  
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 Study visit to the RS 
 1967–1970 1970–1980  1980–1996 
Women    
Never smoking 1 (ref) 0.76(0.40-1.43) 0.48(0.22-1.05) 
Ever smoking 0.54(0.22-1.30) 0.76(0.40-1.42) 0.94(0.48-1.86) 
Men    
never smoking 1.41(0.50-3.97) 0.61(0.28-1.37) 0.54(0.20-1.46) 
Ever smoking 0.28(0.09-0.86) 0.32(0.15-0.67) 0.47(0.22-1.03) 
 
Table A.7.  The association of smoking status with incident GCA stratified for 
decade of study visit to the RS.  Estimates of effects are presented as standardized* 
IRR with 95% confidence intervals.   
* standardization was for age (done in 4 strata i) 50 to 60 year, ii) 61 to 70 years, iii) 71 
to 80 years and iv) after 80 years) hypertension, cholesterol (in quartiles), BMI (in in 4 
categories: underweight, normal weight, overweight and obese) and ESR ( in three 
categories: 0–10, 11–20 and 21 and greater) 
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Supplemental Analysis 2- Survival analysis accounting for the competing 
risk of death 
During follow-up, 11,285 (58.7%) of the 19,241 subjects died and the remaining 
7,956 subjects were censored on December 31st 2008.  Cardiovascular risk 
factors were associated with death in this cohort (data not shown).  
Subdistribution hazards ratios (sdHR) based on the Fine and Gray method are 
shown in Table A.6.  As expected, positive associations are somewhat 
attenuated compared with the cause-specific hazard ratios.  Analysis accounting 
for the competing risk of death suggested even stronger inverse association 
between smoking and GCA among men.   
 
Supplemental analysis - Cardiovascular risk factors as time-varying 
predictors 
Of the 19,241 subjects, 6,154 came for a total of 19,413 study visit, median 2 
(range 2–6). .  The incidence of GCA was similar among those that came for one 
vs. more study visits (Table A.7). The association of cardiovascular risk factors 
stratified according to whether subjects came for one or more study visits is 
shown in Table A.8. Among women, the effect of smoking was different between 
those that came for one study visit vs. those that came for more study visits 
although confidence intervals are wide.   
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 One visit Many visits 
 GCA PY IR GCA PY IR 
Women       
50 to 60 4 32,936 12.1  0 23,279 0.0
60 to 70  23 53,557 42.9 15 27,588 54.4
70 to 80  49 47,145 103.9 26 22,678 114.7
over 80 9 19,945 45.1 10 11,001 90.9
Men   
50 to 60 1 31,263 3.2 0 24,869 0.0
60 to 70  9 44,215 20.4 6 28,324 21.2
70 to 80  17 36,010 47.2 8 21,110 37.9
over 80 10 11,384 87.8 7 8,824 79.3
Both 
sexes 
  
50 to 60 5 64,199 7.8 0 48,148 0.0
60 to 70  32 97,773 32.7 21 55,912 37.6
70 to 80  66 83,154 79.4 34 43,788 77.6
over 80 19 31,328 60.6 17 19,825 85.8
 
Table A.8. Age- and sex stratified incidence rate of GCA among those that came 
for a single study visit and those that came for repeated visits in the Reykjavik 
study Incidence rate is presented as events/100,000 person-years (GCA= Giant cell 
arteritis, PY=Person-years, IR=incidence rate).   
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 Women Men 
 One visit 
(N=7,069 
PY=153,582) 
Many visits 
(N=2,937 
PY=84,546) 
One visit 
(N=6,018 
PY=122,872) 
Many visits 
(N=3,217 
PY=83,127) 
Hypertension 1.05(0.68-1.64) 0.69(0.39-1.23) 1.92 (0.99-3.69) 2.18 (0.88-5.42)
Ever smoking 1.62(1.04-2.52) 0.64(0.36-1.12) 0.81 (0.40-1.65) 0.38 (0.16-0.90)
Cholesterol (mmol/L)     
 <5.7 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
  5.7-6.3 1.04 (0.57-1.90) 1.68(0.52-5.45) 0.73 (0.30-1.83) 0.25(0.03-2.28) 
  6.4-7.1 0.85 (0.46-1.58) 1.63(0.53-5.05) 1.06 (0.46-2.45) 3.09(0.98-9.72) 
  >7.2 0.73 (0.39-1.36) 2.83(0.99-8.11) 0.95 (0.37-2.45) 1.79(0.48-6.68) 
BMI     
<18.5 -- 0.75(0.10-5.54) --  
18.5-24.9 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
25.0-29.9 0.75 (0.47-1.21) 0.60(0.32-1.13) 0.83 (0.42-1.64) 2.38(0.78-7.30) 
≥30 0.40 (0.16-1.00) 0.65(0.29-1.50) 0.99 (0.33-2.95) 2.54(0.57-11.3) 
ESR (mm/hr)     
0-10 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
11-20 1.11 (0.66-1.86) 0.90(0.46-1.75) 1.81 (0.82-3.97) 1.01(0.23-4.53) 
>20 1.89 (1.08-3.29) 1.40(0.66-2.95) -- 9.72(3.80-24.9) 
 
Table A.9.  Association of risk factors with GCA according to those who came for 
a single vs. multiple study visits. All effect estimates (hazard ratios) are adjusted for 
age and the other risk factors included in the table 
 
Supplemental analysis 3- Restricted Analysis to person-time contributed 
after January 1st 1980.  
Temporal artery biopsies were exceedingly rarely obtained on members of the 
Reykjavik study before 1980 despite substantial portion of the RS cohort having 
achieved the age at which the incidence of GCA in Iceland is high. There were 
18,632 subjects that contributed person-time after 1980:  Almost identical effect 
estimates of cardiovascular risk factors were obtained in the analysis restricted to 
the person-time contributed after January 1st, 1980 in comparison to the whole 
person-time contributed are shown in Table A.10.   
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Table A.10: Effect of cardiovascular risk factors on incidence GCA during the total 
follow-up time and after January 1st, 1980 only.  The effect of cardiovascular risk 
factors is expressed with age standardized* incidence rate ratios and 95% confidence 
intervals.  (N=number of subjects, PY=person-years, BMI=body mass index, 
ESR=erythrocyte sedimentation rate) 
  
 Women Men 
 
Entire follow-
up 
 
(N=10,006 
PY=238,128) 
Person-time 
contributed 
after 1980 
(N=9,825 
PY=207,603) 
Entire follow-up 
 
(N=9,235 
PY=205,999) 
Person-time 
contributed 
after 1980 
(N=8,807 
PY=170,831) 
Hypertension 0.88(0.61-1.25) 0.92(0.64-1.31) 2.00(1.18-3.37) 2.03(1.20-3.45) 
Ever smoking 1.12(0.80-1.57) 1.12(0.80-1.57) 0.51(0.30-0.87) 0.50(0.29-0.84) 
Cholesterol  
(mmol/L) 
    
 <5.7 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
  5.7-6.3 0.96(0.58-1.61) 0.99(0.59-1.66) 0.89(0.43-1.84) 0.83(0.39-1.74) 
  6.4-7.1 1.06(0.65-1.72) 1.10(0.67-1.80) 1.14(0.58-2.27) 1.15(0.58-2.29) 
  >7.2 0.89(0.54-1.45) 0.96(0.58-1.57) 0.88(0.40-1.92) 0.90(0.41-1.96) 
BMI     
-underweight (<18.5) *** *** *** *** 
-normal weight (18.5-
24.9) 
1 (ref)  1 (ref)  
-overweight (25.0-
24.9) 
0.70(0.48-1.02) 0.71(0.49-1.03) 0.90(0.52-1.54) 0.94(0.54-1.62) 
-obese (≥30) 0.31(0.14-0.71) 0.31(0.14-0.72) 0.85(0.33-2.22) 0.89(0.34-2.33) 
ESR (mm/hr)     
0-10 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
11-20 0.99(0.66-1.48) 1.01(0.67-1.52) 1.44(0.76-2.73) 1.50(0.79-2.84) 
>20 1.61(1.04-2.48) 1.74(1.12-2.69) 0.42(0.06-3.03) 0.52(0.07-3.76) 
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Discussion 
This study confirms a very high incidence of GCA in Iceland, 43,6/100,000 
person-years after the age of 50, even higher than previously reported 
(27/100,000 person-years after the age of 50, (14)).  Women have overall about 
twice the incidence of GCA compared with men, but after the age of 70, the 
incidence is similar in men and women.  We found that high BMI is protective for 
the occurrence of GCA and smoking appears to be protective for the occurrence 
of the disease among men but not women. 
Findings from this study add to the knowledge on the occurrence of GCA.  It is 
well established that women are at increased risk of GCA compared with men(4, 
15) Previous studies that have reported age- and sex- specific incidence of GCA 
have found women at increased risk compared with men in all age categories 
and that peak incidence occurs at 70–74 years of age and then declines both in 
men and women (4, 16, 17).  In contrast, this study finds that the peak incidence 
of GCA occurs after the age of 80 among men. We found that secular incidence 
of GCA fluctuated with peaks in 1983, 1990, 1998 and 2005.   
 
The finding of an inverse association between higher BMI and GCA has been 
previously reported (3) and contrasts with findings for some other inflammatory 
diseases such as rheumatoid arthritis and psoriatic arthritis where obesity 
appears to increase the risk of disease (18–20). The finding of an inverse 
association between smoking and incident GCA among men was unexpected 
although sex has been reported as an effect-measure modifier for the association 
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of interest.  However, several potential biases may threat the validity of this 
finding and thus prevent from making a valid conclusion on this relation (see 
below).   
 
This study has important strengths.  The RS cohort is population-based cohort 
and information on cardiovascular risk factors was obtained from all members of 
the cohort in a standardized fashion during a study visit to the RS.  The follow-up 
is long and complete The GCA outcome was based on review of all temporal 
artery biopsies performed in the country on members of the RS cohort.  A single 
pathologist with expertise in vascular pathology examined the biopsies in a 
protocolled fashion.  The pathologist was blinded to both exposure information 
and original biopsy conclusion (that is whether the biopsy was reported to be 
diagnostic of GCA).   
This study also has some important limitations.  The study visits occurred over a 
period of 30 years and information on cardiovascular risk factors and ESR was 
usually obtained many years (often decades) before incident GCA. During the 
follow-up time, considerable changes occurred in smoking habits, resulting in 
inherent misclassification in this study with respect to smoking:  A hypothetical 
example to illustrate this would be 2 men, A and B, both born in 1920 who both 
started smoking in 1945, quit smoking in 1970 and both developed GCA in 1995.  
Man A comes for a RS study visit in 1969 and is classified as a current smoker.  
Man B comes for a study visit in 1985, and is classified as a former smoker.  
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Therefore, dichotomizing smoking to ever vs. never is probably appropriate in 
this longitudinal cohort.  In our analysis male smokers appear to have about half 
the risk of GCA compared with nonsmokers and findings from the analysis in 
which death is treated as a competing risk suggested even more protected effect 
of smoking.  One possibility of this finding would be that clinicians caring for a 
patient who smokes would be less likely to obtain a temporal artery biopsy for 
male who smokes and might be inclined to perform diagnostic procedures 
pertaining to diseases with known relationship with smoking.  Male smokers were 
less likely to undergo temporal artery biopsy, but only marginally so. However, 
there are several other possible sources of bias with respect to the smoking-GCA 
association in men that could exist in the RS cohort.  The strong effect 
modification by calendar time on this relationship among women is of particular 
concern: smoking was inversely associated with GCA among women that came 
for study visit before 1970, but positively associated with GCA among those that 
came for study visit after 1980.  This is not biologically plausible and we do not 
have an explanation for this finding; in the subset of patients that came for 
multiple visits, no attenuation of the smoking-GCA association is found.  It is 
possible that effect-measure modification by decade of study examination is not 
seen in men because they get GCA at older age compared with the women in 
this cohort, and almost always a very long time after their RS study visit.  It 
should be pointed out that in calculation of the effects of covariates for each 
subject with the outcome of GCA, only data from those alive at that age and at 
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risk for the event are used.  Therefore, this smoking-GCA association among 
men cannot be explained by the competing event of mortality as those who 
smoke are more likely to die at younger age and not contribute data when they 
achieve the age where the risk of GCA is high.  This was confirmed in a 
supplemental analysis with methods aiming to adjust for this modification of the 
risk set by the competing event, where even stronger inverse relationship 
between smoking and incident GCA among men was found.   
 
The effect of cardiovascular risk factors on risk of cardiovascular disease in this 
population has been found very consistent with estimates obtained in other 
population cohorts(21). Thus, it is possible that smoking is truly protective for the 
occurrence of GCA among men.  It could potentially be viewed as a limitation of 
our study that not all subjects with GCA have positive temporal artery biopsy 
confirmative of the disease.  In an Icelandic study, 5% of those with GCA did not 
have biopsy-confirmed disease(14).  Other studies have also found high 
sensitivity of temporal artery biopsy(22).  Nonetheless, it is likely we missed 
some with GCA.  However, given lack of diagnostic criteria for GCA (current ACR 
criteria are classification criteria designed to classify subjects with GCA from a 
reference population where all members have been diagnosed with some kind of 
vasculitis(23)), it is probably a greater risk for misclassification if the biopsy 
criteria was relaxed.  We believe this view is shared by many investigators in the 
field as many studies rely on biopsy-proven GCA as their exposure or outcome 
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definition.  In this analysis, the effect of each cardiovascular risk factor is 
presented after age-standardization and after standardization across strata of the 
cardiovascular risk factors.  It has been advised against to provide the effect of 
each risk factor on the outcome adjusted for all other potential risk factors.  If 
some of the risk factors are on the causal pathway of each other the effect 
estimates for the risk factors from a single model requires different 
interpretation(24). Figure A4 shows a directed acyclic graph (DAG) of a 
hypothetical causal structure between age, hypertension and BMI on GCA. In a 
Cox regression model (or by any other method of multiple adjustments), the 
estimate for HTN should be interpreted as the effect of hypertension adjusted for 
the effect of age and BMI. The estimate for BMI should be interpreted as the 
proportion of the effect of BMI that is not mediated by HTN and the estimate for 
age should be interpreted as the proportion of the effect of age that neither 
mediated by BMI nor HTN.  
 
Figure A4. Hypothetical causal structure between risk factors of GCA.  
(HTN=Hypertension, BMI=Body mass index, GCA=Giant cell arteritis) 
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For studying cardiovascular risk factors and cardiovascular events, similar causal 
structure between variables has been proposed.(25).   In this analysis of risk 
factors for incident GCA, there exists extremely limited, if any, prior data to base 
on candidate causal diagrams including cardiovascular risk factors and ESR. 
Furthermore, findings from crude analysis in which BMI is protective and the 
substantial effect modification by sex with respect to the effect of smoking and 
hypertension, argues against the basing analytic process on the approach that 
would be taken if cardiovascular disease was the outcome.  
 
In summary, this study confirms the high incidence of GCA in Iceland and reveals 
that men get GCA at older age compared with women.  This study validates an 
inverse association of BMI with GCA and reveals an unexpected inverse 
association between smoking and incident GCA in men but not women  
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Abstract 
Objective:  To measure the effect of GCA on incident coronary heart disease 
within a longitudinal cohort study where detailed information on cardiovascular 
risk factors has been collected. 
Methods: Data from the Reykjavik Study (RS), a population-based, prospective 
cohort study with a primary focus on cardiovascular disease, were used. 
Exposure status with GCA was defined as a temporal artery biopsy consistent of 
GCA. Subjects contributed person-time as unexposed until they met exposure 
criteria. The association of GCA with incident CHD is expressed as incidence 
rate ratios (IRR) with 95% confidence intervals, standardized across strata of 
age, sex and cardiovascular risk factors.  
Results: One hundred seventy six subjects contributed person time as exposed 
with GCA in this analysis. Subjects were followed for a median of 6.2 (IQR: 2.7–
11.5) years after being diagnosed with GCA; the referent subjects were followed 
for mean of 22.5 (IQR: 14.7–28.2) years. During follow-up approximately 25% of 
study subjects had incident CHD. Compared with those without GCA, risk of 
CHD was increased by 77% (IRR= 1.77: 95% CI: 1.17-2.67) among women; 
such an association was not observed among men (IRR 1.08:95% CI: 0.60–
1.95). Standardization over strata of cardiovascular risk factors and inflammation 
modestly attenuated the effect estimates among women.  
Conclusion: GCA is associated with incident CHD among women but estimates 
for men are too imprecise to draw definite conclusions.     
   55
Introduction 
Large-artery stenoses and aneurysms are well described complications of GCA 
(1, 2), but studies exploring the association of GCA with clinically important 
cardiovascular events have provided conflicting results (3-5): Large population-
based studies from Canada and the UK that relied on diagnostic codes for GCA 
in the medical records found risk of cardiovascular events increased 2-fold  (3, 
4). In contrast, a preliminary report from Olmsted County, Minnesota, found no 
increased risk of acute coronary events among patients with biopsy confirmed 
GCA compared with those without GCA (5). In addition, previous studies have 
also shown that traditional cardiovascular risk factors are associated with 
occurrence and complications of GCA (6-9). Using data collected from Reykjavik 
Study we found an inverse association of body mass index (BMI) with incident 
GCA among both men and women as well as inverse association between 
smoking and risk of GCA among men. Therefore, collection of information on 
cardiovascular risk factors and appropriate adjustment for these factors are 
important when investigators examine the effect of GCA on the risk of 
cardiovascular disease. Study A of this thesis found that among those with a 
temporal artery biopsy consistent with GCA, the diagnosis was not made 
according the original biopsy report in a proportion of these subjects. That 
provides an opportunity to assess how GCA that is not reported at the time of 
biopsy (and therefore possibly untreated) affects cardiovascular risk compared to 
the risk of incident CHD among those with early biopsy confirmation of GCA. The 
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objective of this study was to determine the association between GCA and 
incident coronary heart disease (CHD) in a population cohort with information on 
risk factors for cardiovascular disease and to explore how early biopsy 
confirmation of GCA affects risk of CHD. 
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Methods 
Study Design 
We conducted a cohort study to examine the effect of GCA on incident CHD 
among participants in the Reykjavik Study.  
Study population 
The Reykjavik Study (RS) has been described in a detail (see page 5). Briefly, 
persons, who were born in 1907–1935 and living in Reykjavik or in adjacent 
communities, Iceland on December 1, 1967, were invited to participate.  Subjects 
came for a study visit in 1967–1996 and information on cardiovascular risk 
factors was obtained.  Individuals with GCA or CHD at baseline were excluded 
from this analysis.  
For a supplemental analysis accounting for the competing risk of non-
cardiovascular mortality, a cohort design with a matched reference group was 
used. For each subject with GCA we randomly selected 25 subjects alive and 
free of GCA, matched on sex and birth year.  
 
Exposure Assessment 
The exposure of GCA was defined as diagnostic temporal biopsy in the three 
pathologic laboratories in Iceland. All temporal artery biopsies obtained from 
members of the RS cohort were re-examined by a single pathologist as 
previously described (see page 22). For a temporal artery biopsy to be 
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considered diagnostic for GCA, for the purpose of this study, it must have 
infiltration of inflammatory cells to the vessel wall. To explore if temporal artery 
biopsies were thought to be consistent with GCA at the time they were obtained, 
the original pathology reports were reviewed.  An early biopsy confirmed GCA 
was defined as when at least one of the following features were described in the 
original biopsy report: i) vasculitis, ii) presence of inflammatory infiltrate in the 
vessel wall, or iii) giant cells.  
Covariate assessment 
Information on hypertension, smoking, diabetes mellitus (DM), cholesterol, BMI 
and erythrocyte sedimentation rate (ESR) was obtained as previously described 
(see page 20) at baseline RS study visit before incident GCA. 
Follow-up and outcome assessment 
All subjects were followed from the time of RS study visit or from the time they 
reached 50 years of age, whichever occurred later, until the time of death, 
December 31st, 2007 or the occurrence of CHD, whichever occurred first.   A 
CHD event was defined as a myocardial infarction (MI), revascularization 
procedure, or sudden cardiac death. Diagnostic criteria for MI included clinical 
symptoms, typical changes on an ECG, enzyme activity and signs of possible or 
definite MI on autopsy.  The quality of the registry of MI in the RS Study has been 
subject to external oversight and its accuracy has been excellent (10). 
Revascularization procedures included percutaneous coronary interventions 
(PCI) and coronary artery bypass grafting (CABG). On behalf of the Icelandic 
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Heart Association, there is surveillance for those procedures performed at 
Landspitali University Hospital and earlier at Brompton Hospital London, UK 
where Icelanders in need of CABG were referred to in the 1970’s and early 
1980’s.  These two hospitals were the sole providers of coronary artery 
revascularization procedures for the Icelandic population. Information on sudden 
cardiac death was obtained from death certificates.  
Statistical analysis 
We excluded follow-up before age 50 because GCA rarely occurs before age 50. 
Specifically, for subjects with GCA the follow-up time started from the date of 
TAB that was consistent with GCA by our examination for the purpose of this 
study. For subjects who did not develop GCA during the follow-up their follow-up 
time started from the date of entry if subjects’ age at entry was older than 50 
years old; otherwise their follow-up time started as soon as subjects reached 50 
years of age. In addition, subjects with GCA contributed person-time to the non-
GCA cohort before diagnosis of GCA.  All subjects were followed up until time of 
CHD diagnosis, or death, or end of follow-up, whichever occurred first. The 
incidence rate (IR) was calculated as the number of incident CHD divided by the 
person-years of follow-up for GCA cohort and non-GCA cohort separately.  
The effect of GCA on the risk of CHD was expressed as incidence rate ratio 
(IRR) with 95% confidence intervals (CIs).  To adjust for potential confounding, 
standardized IRRs were calculated, standardizing to the distribution of person-
time among subjects with GCA. Standardized effect estimates were calculated 
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across strata of age and cardiovascular risk factors. Age was divided into four 
strata: 50 to <60, 60 to <70, 70 to <80 and > 80 years old. Smoking was divided 
into two categories: never smokers and ever-smokers. BMI was divided into four 
categories according to the WHO classification: underweight (<18.5kg/m2), 
normal weight (18.5-<25kg/m2), overweight (25–<30 kg/m2) and obese (>30 
kg/m2). Total cholesterol was divided to strata according to quartiles and ESR 
was stratified as <10, 11–20 and >20 mm/hour. As there was substantial effect-
measure modification by sex, the effect of GCA on incident CHD was calculated 
separately for women and men. Standardized effect estimates were calculated 
across strata of i) age; ii) age and cardiovascular risk factors; and iii) age, 
cardiovascular risk factors and ESR. To explore the magnitude of confounding, 
we calculated the rate ratio due to confounding (RRc), which is equal to 
IRR/IRRSTD.  Stratified analysis was also performed with GCA status stratified 
according to whether the diagnosis was supported by the original pathology 
report (early biopsy confirmed GCA vs. not originally reported GCA), using the 
same standardization weights as in the other analyses.  
In a supplemental analysis using matched cohort design, a Cox proportional 
hazards regression with age of CHD as the outcome variable and GCA status as 
a time-varying predictor.  We chose subjects’ age as the time-scale for the 
regression analysis; age was also included as an independent variable.  To allow 
for better comparison with analysis accounting for the competing event of 
mortality Cox proportional regression was also performed with time on study as 
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the time-scale for the regression analysis. In an attempt to measure the effect of 
GCA on CHD accounting for the effect of GCA on the competing event (death 
from other causes than “sudden cardiac death” that is embedded in the CHD 
definition), for reasons previously outlined (see page 26), the subdistribution 
hazard ratio (sdHR) was calculated according to the Fine and Gray method (11).   
SAS 9.2 (SAS institute Cary, NC) was used for calculations, a SAS macro 
(appendix A) was developed for calculations of standardized rate ratios. The 
macro was developed based on (and tested for errors against Episheet (12) for 
calculations of standardized rate ratios and their confidence interval.  The 
statistical package cmprsk in R was used for calculations subdistribution hazards 
ratios according to the Fine and Gray method (11).   
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Results 
Approximately 70% (19,360) of participants who were originally invited to 
participate in the Reykjavik Study came for a study visit from October 26th, 1967 
to April 23rd, 1996.  Of them 12 subjects had a temporal artery biopsy diagnostic 
of GCA before their RS study visit, 107 subjects died before the age of 50, and 
461 subjects had CHD at baseline. Therefore, 18,780 subjects are included in 
this analysis.   
Baseline characteristics 
During the follow-up period 189 subjects developed incident GCA. Of them, 14 
subjects (8 women and 6 men) had incident CHD before their GCA diagnosis 
and contributed person-time only to non-GCA cohort. Thus, 175 subjects had 
incident GCA for the purpose of this analysis. The baseline characteristics of 
GCA and comparison subjects are shown in Table B.1.  The mean age at 
diagnosis of subjects with GCA was 73.0 (sd=6.6) and most were women, 125 
(71.4%). At baseline there was minimal missing data with respect to serum 
cholesterol (n=40, 0.21%), BMI (n=142, 0.76%) and ESR (n=125, 0.67%),  
Distribution of cardiovascular risk factors was similar among CGA and 
comparison subjects.  
Incident coronary heart disease 
Subjects (n=175) with GCA were followed for 1,399 person-years, of which 1,151 
person-years (83%) were contributed by study subjects after achieving the age of 
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70. Median follow-up time for subjects with GCA after the diagnosis of GCA was 
6.2 years (IQR: 2.7–11.5 years).  Comparison subjects (n=18,605) were followed 
for 399,456 person-years, of which 147,474 (37%) were contributed by study 
subjects after achieving the age of 70. The median follow-up time for the 
comparison subjects was 22.5 (IQR: 14.7–28.2) years. During follow-up 5,027 
subjects (34 among GCA cohort and 4,993 in comparison cohort) developed 
incident CHD. The crude IR of CHD was 24.3/1000 person-years among GCA 
cohort and 12.5/1000 person-years among non-GCA cohort, respectively. 
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 GCA 
(N=175 
PY=1,399) 
No GCA 
(N=18,666 
PY=399,456) 
Women 1,016 (73%) 223,545 (56%) 
Age   
 -50 to 60 years 9   (1%) 109,307 (27%) 
 -60 to 70 years 239 (17%) 142,675 (36%) 
 -70 to 80 years 724 (52%) 107,064 (27%) 
 > 80 years 427 (31%) 40,410 (10%) 
Hypertension  526 (38%) 150,560 (38%) 
Smoking   
  -never 645 (46%) 146,966 (37%) 
  -former 320 (23%) 78,220 (20%) 
  -current smoking 435 (31%) 174,243 (44%) 
Total Cholesterol 
(mmol/L) 
 
 <5.7 342 (24%) 96,254 (24%) 
  5.7–6.3 304 (22%) 99,224 (25%) 
  6.4–7.1 348 (25%) 104,439 (26%) 
  >7.2 405 (29%) 98,885 (25%) 
DM 34   (2%) 11,271   (3%) 
BMI  
 <18.5 0   (0%) 5,482   (1%) 
 18.5–24.9 828 (61%) 192,400 (48%) 
 25–29.9 444 (33%) 158,173 (40%) 
 ≥30 92   (7%) 41,558 (10%) 
ESR  
 0–10 850 (61%) 272,636 (69%) 
 11–20 319 (23%) 86,181 (22%) 
 >21 226 (16%) 38,582 (10%) 
 
Table B.1. Baseline characteristics According to Status of GCA 
Variables are expressed as number of person-years (percentage) in each stratum 
(GCA=Giant cell arteritis, DM=diabetes mellitus, BMI=body mass index, 
ESR=erythrocyte sedimentation rate).  
 
Association of GCA with incident CHD  
Among subjects with GCA, incident CHD was almost exclusively observed 
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among the two highest age strata (70–80 years and over 80 years).  Incidence of 
CHD was higher among subjects with GCA than those without GCA, age- and 
sex standardized IRR=1.32 (95% CI: 0.94–1.84).  Age- and sex- specific IRs and 
IRRs are shown in Table B.2. There was considerable effect-measure 
modification by sex.  The age-standardized IRR of CHD according to GCA was 
1.77 (95% CI: 1.17–2.67) among women and 1.08 (95% CI: 0.60-1.95) among 
men. This different effect between men and women was more prominent for non-
fatal CHD, with IRR for non-fatal CHD of 2.33 (95% CI: 1.46–3.71) among 
women and 0.74 (95% CI: 0.31–1.78) among men. There was positive 
association of GCA with sudden cardiac death in both men and women. Age- 
and sex stratified IRs and IRRs of GCA with non-fatal CHD and sudden cardiac 
death and are shown in Table B.3.   
       GCA No GCA   
 CHD PY IR CHD PY IR RD IRR 
Women         
50 to 60 0 8.49 0 114 55,817 2 -2 
60 to 70  0 150.43 0 374 78,924 4.7 -4.7 
70 to 80  13 540.15 24.1 670 62,937 10.6 13.5 2.27 (1.31-3.94)
over 80 10 316.52 31.6 534 25,866 20.6 11 1.53 (0.82-2.87)
Men    
50 to 60 0 0.66 0 511 53,490 9.6 -9.6 
60 to 70  1 88.85 11.3 1187 63,750 18.6 -7.3 0.61 (0.09-4.32)
70 to 80  3 183.37 16.4 1066 44,127 24.2 -7.8 0.68   (0.22-2.1)
over 80 7 110.7 63.2 537 14,543 36.9 26.3 1.71 (0.81-3.61)
Both 
sexes    
50 to 60 0 9.15 0 625 109,307 5.7 -5.7 
60 to 70  1 239.28 4.2 1561 142,675 10.9 -6.7 0.39 (0.05-2.74)
70 to 80  16 723.52 22.1 1736 107,064 16.2 5.9 1.36 (0.83-2.23)
over 80 17 427.22 39.8 1071 40,410 26.5 13.3 1.5 (0.93-2.43)
Table B.2. Age- and sex-specific incidence of CHD. Age- and sex- stratified number 
of deaths, person-years, Incidence rate of death expressed as number of CHD 
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events/1,000 person-years and the association of GCA with death expressed as IRR 
with 95% confidence intervals in strata of age and sex (GCA=Giant cell arteritis, 
CHD=Coronary heart disease, PY= Person-years, IR=incidence rate, RD=risk 
difference, IRR=incidence rate ratio). 
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 Non-fatal CHD Sudden Cardiac Death 
 GCA 
IR 
No GCA
IR 
 
IRR 
GCA 
IR 
No GCA 
IR 
 
IRR 
Women       
50–60 0 1.8  0 0.3 
61–70 0 4.6  0 0.2 
71–80 24.1 8.5 2.84 (1.64–4.92) 0 2.2 
>80 15.8 7.8 2.03 (0.83–4.92) 15.8 12.8 1.23 (0.51–2.99)
Men   
50–60 0 8.4 0 1.2 
61–70 11.3 17.3 0.65 (0.09–4.64) 0 1.3 
71–80 16.4 20 0.82 (0.26–2.55) 0 4.2 
>80 9 14.1 0.64 (0.09–4.55) 54.2 22.8 2.38 (1.06–5.33)
Both 
sexes   
50–60 0 5 0 0.7 
61–70 4.2 10.3 0.41   (0.06–2.9) 0 0.7 
71–80 22.1 13.2 1.67 (1.02–2.74) 0 3 
>80 14 10.1 1.39   (0.62–3.1) 25.7 16.4 1.57 (0.86–2.84)
Table B.3. Incidence rate of non-fatal coronary heart disease (MI, PCI and CABG) 
and sudden cardiac death. Measures of associations are expressed as the number of 
events/100,000 person years and association of GCA with incident coronary heart 
disease expressed as IRR with 95% confidence intervals in strata of age and sex 
(GCA=Giant cell arteritis, IR=incidence rate, IRR=incidence rate ratio, MI=myocardial 
infarction, PCI=percutaneous coronary intervention, CABG=coronary artery bypass 
grafting) 
 
Stratified and standardized association of cardiovascular risk factors and 
inflammation 
Stratified analysis across different strata of cardiovascular risk factors did not 
reveal great effect measure modification (Table B.4), except that among women 
GCA appeared to have stronger association with CHD among those with low vs. 
high serum cholesterol with age standardized IRR = 2.77 (95% CI: 1.48–5.19) 
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and 1.38 (95% CI: 0.80–2.39) respectively. 
Table B.4. Incidence of CHD stratified according to cardiovascular risk factors. 
Person-years are expressed in thousands. Incidence rates expressed as number of 
event/100,000 person-years and association of giant cell arteritis with incident coronary 
heart disease across strata of sex, cardiovascular risk factors and inflammation 
expressed as crude IRR and standardized IRR across four age-strata (50–60, 60–70, 
 GCA No GCA   
 CHD PY IR CHD PY IR IRR Std IRR 
WOMEN         
HTN         
yes 12 0.36 33.1 877 80.5 10.9 3.04 (1.72-5.37) 2.00(1.13-3.53)
no 11 0.65 16.9 815 143 5.7 2.96 (1.64-5.38) 1.64(0.90-2.98)
Smoking    
ever 17 0.52 32.9 1070 119 9 3.66   (2.26-5.9) 2.15(1.33-3.48)
never 6 0.50 12 622 105 5.9 2.03 (0.91-4.54) 1.16(0.52-2.58)
Cholesterol     
<6.3 mmol/L 10 0.42 24 488 101 4.8 5 (2.67-9.35) 2.77(1.48-5.19)
≥6.3 mmol/L 13 0.60 21.7 1199 122 9.8 2.21 (1.28-3.82) 1.38(0.80-2.39)
BMI    
<25 11* 0.64 17.1 820 122 6.7 2.55 (1.41-4.63) 1.41(0.77-2.55)
≥25 8* 0.34 23.8 848 100 8.4 2.83 (1.41-5.68) 1.78(0.88-3.56)
ESR    
≤20 mm/hour 15 0.80 18.7 1294 190 6.8 2.75 (1.65-4.57) 1.66(1.00-2.76)
>20 mm/hour 7 0.21 33.3 379 31.6 12 2.78 (1.31-5.86) 1.57(0.74-3.33)
MEN    
HTN    
yes 7 0.16 42.9 1588 70.0 22.7 1.89   (0.9-3.97) 1.25(0.59-2.64)
no 4 0.22 18.1 1713 106 16.2 1.12 (0.42-2.98) 0.84(0.32-2.25)
Smoking    
ever 7 0.24 29.5 2647 134 19.8 1.49 (0.71-3.13) 1.07(0.51-2.24)
never 4 0.15 27.4 653 42.1 15.5 1.77 (0.66-4.72) 1.22(0.46-3.27)
Chol.    
low 5 0.23 21.8 1421 94.1 15.1 1.44   (0.6-3.47) 1.05(0.44-2.54)
high 6 0.15 38.9 1874 81.4 23 1.69 (0.76-3.77) 1.61(0.23-11.5)
BMI    
<25 5 0.18 27.2 1248 76.1 16.4 1.66 (0.69-3.99) 1.19(0.50-2.88)
≥25 6 0.20 30 2041 99.2 20.6 1.46 (0.65-3.25) 1.02(0.46-2.27)
ESR    
≤20  mm/hour 10 0.37 27.2 3078 168 18.3 1.49   (0.8-2.77) 1.05(0.56-1.95)
>20  mm/hour 1 0.01 62.3 210 6.98 30.1 2.07 (0.29-14.8) 1.61(0.23-11.5)
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70–80 and older than 80) (GCA=Giant cell arteritis, CHD=Coronary Heart disease 
HTN=hypertension, BMI=body mass index, ESR=erythrocyte sedimentation rate, 
IR=incidence rate, IRR=incidence rate ratio Std IRR= age standardized incidence rate 
ratio).  
*Among women with GCA who had incident CHD, 4 out of 23 had missing data on BMI.  
 
A standardization across strata of cardiovascular risk factors (hypertension, 
smoking, and cholesterol) did not materially attenuate the effect estimate: 
IRR=1.80 (95% CI: 1.19–2.73) among women and IRR=1.13 (0.62–2.04) among 
men. Further standardization for inflammation at baseline (as measured by the 
ESR) also resulted in minimal changes of the effect estimate in either women 
(IRR=1.66, 95% CI: 1.09–2.55) or men (IRR=1.12, 95% CI: 0.62–2.04). 
Standardization across strata of cardiovascular risk factors and inflammation also 
had minimal effect on the individual CHD-defining events (Table B.5).  Although 
missing data for covariates was minimal in the whole study cohort, there was 
substantial missing data for BMI among women with GCA who sustained incident 
CHD, among whom 4 out of 23 (17.3%) had missing data on BMI. In a sensitivity 
analysis imputing data for BMI, additionally adjusting for BMI did not change the 
estimates between GCA and CHD very much (Table B.6).  
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 Standardization 1 Standardization 2 Standardization 3
    
WOMEN    
CHD 1.77(1.17-2.67) 1.80(1.19-2.73) 1.66(1.09-2.55)* 
-MI 2.17(1.08-4.36) 2.28(1.31-3.95) 1.92(1.08-3.43)* 
-revascularization 3.17(1.30-7.69) 2.54(1.05-6.18) 2.63(1.07-6.42) 
-sudden cardiac death 0.95(0.39-2.29) 0.99(0.41-2.38) 0.99(0.41-2.38) 
-nonfatal CHD 2.33(1.46-3.71) 2.34(1.47-3.74) 2.34(1.47-3.74) 
    
MEN    
CHD 1.08(0.60-1.95) 1.13(0.62-2.04) 1.12(0.62-2.04) 
-MI 0.57(0.14-2.30 0.47(0.12-1.88) 0.51(0.13-2.03) 
-revascularization 1.16(0.29-4.65) 1.47(0.47-4.59) 1.45(0.47-4.55) 
-sudden cardiac death 1.62(0.72-3.66) 1.73(0.77-3.89) 1.59(0.70-3.60) 
-nonfatal CHD 0.74(0.31-1.78) 0.79(0.33-1.91) 0.79(0.33-1.91) 
Table B.5. Association of giant cell arteritis with incident CHD with three different 
methods for standardization. Measures of associations are expressed as incidence 
rate ratios with 95% confidence intervals standardized across four age-strata (50-60, 60-
70, 70-80 and older than 80), cardiovascular risk factors and ESR  
Standardization 1 is across strata of age 
Standardization 2 is across strata of age, ever smoking, hypertension and cholesterol.  
Standardization 3 is across strata of age, ever smoking, hypertension, cholesterol and 
erythrocyte sedimentation rate. 
(MI=myocardial infarction, CHD=coronary heart disease, ESR=Erythrocyte 
sedimentation rate) 
*Only 22 out of 23 CHD events (12 out of 13 MIs) included in the analysis as one woman 
with GCA had missing data for ESR.  
 
For the analysis on association of GCA with CHD based on statistical modeling 
with and without accounting for the competing event of mortality, we compared a 
cohort of 175 patients with GCA and 4,375 matched comparison subjects. 
Results were almost identical to the tabular analysis.   
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 Standardization/ 
Model 1 
Standardization/ 
Model 2 
Standardization/ 
Model 3 Model 4 
Women     
IRR 1.66 (1.09-2.53) 1.50 (0.94-2.40) 1.22 (0.73-2.04)* 
HR# 1.72   (1.13-2.6) 1.57 (0.99-2.49) 1.45 (0.90-2.33)* 1.42 (0.88-2.78)*
HR$ 1.68 (1.10-2.56) 1.51 (0.95-2.40) 1.39 (0.87-2.24)* 1.36 (0.85-2.18)*
HR† 1,54 (1,00-2,36) 1,57 (1,02-2,42) 1.41 (0.89-2.22)* 1.40 (0.89-2.19)*
Men  
IRR 0.96 (0.53-1.76) 0.94 (0.51-1.75) 0.89 (0.47-1.70) 
HR# 1.00 (0.55-1.93) 0.99 (0.54-1.80) 0.99 (0.54-1.80) 0.98 (0.53-1.78)
HR$ 1.01 (0.55-1.84) 0.99 (0.54-1.80) 0.99 (0.54-1.80) 0.97 (0.53-1.77)
HR† 0.78 (0.42-1.44) 0.75 (0.41-1.39) 0.75 (0.41-1.40) 0.76 (0.41-1.38)
 
Table B.6. Association of GCA with incident CHD with IRR and HR from different 
survival models in a matched cohort analysis.  
Standardization/model 1 is across strata or adjusted for of age (in four strata in the 
tabular analysis and as continuous linear predictor in the regression models) 
Standardization/model 2 is across strata/adjusted for age, ever smoking, hypertension 
and cholesterol.   
Standardization/model 3 is across strata/adjusted for of age, ever smoking, 
hypertension, cholesterol and erythrocyte sedimentation rate. 
Model 4 is adjusted for of age, ever smoking, hypertension, cholesterol and erythrocyte 
sedimentation rate with all continuous variables entered as linear predictors.  
#HR with subjects’ age as the time-scale for analysis 
$HR with follow-up time as the time-scale for analysis 
†HR accounting for the competing event of mortality with follow-up time as the time-scale 
for analysis.  
*Only 22 out of 23 CHD events included in the analysis as one woman with GCA and 
CHD had missing data for ESR.   
(GCA=Giant cell arteritis, CHD=Coronary heart disease, IRR=Incidence rate ratio, 
HR=hazards ratios) 
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Effect of early biopsy confirmed vs. not biopsy-reported GCA with incident 
CHD.  
Among the 176 subjects with GCA (women: 126) 118 subjects’ diagnosis of GCA 
(women: 92) was made based on either the original biopsy report or description 
of inflammatory infiltrate on temporal artery.  For the remaining 58 subjects 
(women: 34), there was discordance between the examination of the temporal 
arteries for the purpose of this study and the original pathology report.  Biopsies 
from all those subjects met exposure criteria for GCA in this study, but the 
original biopsy report mentioned neither GCA nor inflammatory infiltrate of the 
temporal artery; thus the temporal artery was normal or with intimal hyperplasia 
only according to the original report.  For both men and women the association 
between GCA and risk of CHD varied according to how GCA was defined in the 
original pathology report. As shown in Table B.7, subjects with GCA confirmed 
by early biopsy had lower risk of incident CHD than those whose GCA was not 
confirmed by biopsy report. 
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 Women Men 
 Standardized IRR Standardized IRR 
No GCA 1 (ref) 1 (ref) 
GCA   
-Early biopsy confirmed GCA 1.57 (0.94-2.60) 0.70 (0.29-1.69) 
-No GCA according to 
original biopsy report 2.46 (1.21-4.99) 1.38 (0.62-3.08) 
Table B.7. Association of GCA with incident CHD stratified according to results of 
original biopsy report. Measures of association are expressed as IRR with 95% 
confidence intervals in strata of sex and whether features of GCA were described on the 
original biopsy report. Estimates are standardized across four age-strata (50–60, 60–70, 
70–80 and older than 80). (GCA=giant cell arteritis, IRR=incidence rate ratio).  
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Discussion 
 
This study found an association between GCA and incident CHD among women. 
The effect estimate for risk of GCA on CHD among men was close to 1.   The 
effect estimates are modest but adjustment for cardiovascular risk factors, 
inflammation and supplemental analysis accounting for the competing risk of 
mortality did not result in attenuation of the risk estimates. In addition to different 
effect estimates for women and men, there also was substantial effect-measure 
modification according to whether features of GCA were described in the original 
pathology report, signaling that there might be benefits of early detection and 
treatment of GCA with respect to cardiovascular risk.  
This study has important strengths. Information on cardiovascular risk factors 
was obtained from nearly all members of the cohort in standardized fashion 
regardless of exposure status. Treatment with high dose glucocorticoids is the 
standard of care for newly diagnosed patients with GCA. Finding a substantial 
number of subjects with GCA, for which the diagnosis was not originally reported 
provides a rare opportunity for insight in to the natural history of probably-
untreated GCA in the context of developing cardiovascular disease.  
This study also has several limitations. This study is small; of 176 GCA patients 
(men: 50) with incident GCA only 34 (men: 11) had developed CHD events.  No 
data on clinical presentation and treatment are available to us and we have no 
information on the clinical diagnosis by the treating physician, which might have 
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set the diagnosis based on clinical findings However, a nationwide study on the 
occurrence of GCA in Iceland 1983–1990, for which some overlap exists to this 
study (of the 118 with early biopsy confirmed GCA in our cohort, 35 occurred 
during 1984–1990), found that 95% of subjects with GCA in Iceland during that 
period had biopsy confirmed disease (13). Therefore, we deduce that for a 
substantial number of subjects with GCA in our study for whom the diagnosis 
was not found on the original biopsy report the diagnosis was in fact not made by 
the clinician. Although missing data were rare, missing BMI information was 
associated with GCA status among women. We do not have an explanation for 
this differential missing data between subjects with GCA and comparison 
subjects. Several sensitivity analyses with imputed data for BMI did not suggest 
that the association between GCA and CHD is confounded by BMI.  
The substantial effect-measure modification according to sex is not readily 
explained. Some of this effect is driven by the fact that women represent a higher 
proportion of those for whom the diagnosis was not made according to original 
biopsy report compared with those with early biopsy confirmed disease. This 
study also indicates that the effect of GCA might be associated with different 
types of CHD defining events in women and men. Women have increased risk of 
non-fatal presentation of CHD (MI, and revascularization procedure) whereas 
among men the effect estimates demonstrated an increased risk of sudden 
cardiac death. However, all effect estimates for different types of CHD-defining 
events have wide confidence intervals.  
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This study provides information as to whether risk of GCA on CHD is confounded 
by cardiovascular risk factors. It finds that the association of GCA on CHD in 
women is not driven by different distribution cardiovascular risk factors between 
the subjects with GCA and referent subjects. The lack of confounding by 
inflammation as measured by the ESR should not be interpreted as the effect of 
GCA on incident CHD is being mediated by systemic inflammation. The ESR 
measurements were obtained at the RS study visit, in most cases many years 
before the onset of GCA, and subject who developed GCA within our cohort 
almost certainly sustained much greater systemic inflammatory response at the 
time of onset of GCA.  
Glucocorticoids have well-documented pro-atherosclerotic effects such as 
elevation in blood lipids, blood glucose and can cause hypertension (14). 
Treatment with glucocorticoids is often considered as potential cause for 
increased cardiovascular disease observed among patient with chronic 
inflammatory diseases. Our findings, however, indicate the opposite, that 
treatment with glucocorticoids might be of value for reducing the risk of CHD as 
observed among those with early biopsy confirmed GCA, and therefore those 
who are more likely to have received early treatment with systemic 
glucocorticoids have less risk of CHD, providing a suggestion that untreated 
inflammation may be detrimental for CHD risk.  
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In summary, GCA is associated with modestly increased risk of CHD among 
women but there is inadequate information to draw a conclusion for men. Early 
disease detection might be of benefit with respect to cardiovascular risk.  
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Abstract 
Objective:  To measure the effect of giant cell arteritis (GCA) and its 
histopathology on all-cause and cardiovascular mortality within a population 
cohort with detailed information on temporal artery biopsies (TAB).   
Methods: Data from the Reykjavik Study were used. GCA status was defined 
from examination of TABs by a single expert pathologist. Original histological 
diagnosis was obtained from the original pathology report. Cardiovascular 
mortality was assessed from death certificates. Subjects contributed person-time 
as unexposed until they met exposure criteria. Effect of GCA, compared with 
those without GCA, is expressed as incidence rate ratios (IRR) (95% confidence 
intervals (CI)) standardized for age and sex. Effects of TAB findings were 
compared with those who did not undergo TAB.  
Results: Of 19,241 included subjects, 692 underwent TAB and 196 had GCA. 
Subjects were followed for a median of 7.1 (IQR: 3.5–12.4) years after exposure 
of GCA, but referent subjects for 24.3 (IQR: 17.6–29.8) years. GCA was 
associated with all-cause and cardiovascular mortality, with IRRs=1.45 (1.20–
1.75) and IRR=1.50 (1.13–1.99) respectively. For 71 subjects with GCA but a 
negative pathology report, there was substantially increased mortality risk with 
IRR=2.18 (1.65–2.90) compared with IRR=1.10(0.85–1.42) for those (n=125) 
with an original histological diagnosis of GCA. There was an inverse association 
between TAB inflammation and mortality risks with IRRs of 2.15 (1.60–2.88), 
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1.26 (0.85–1.85) and 1.13 (0.81–1.57), for mild, moderate and severe 
inflammatory intensity, respectively.  
Conclusion: GCA is associated with modestly increased mortality risks that are 
driven by GCA patients without original histological diagnosis of GCA.  
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Introduction 
Most (1-6), but not all (7, 8) studies have found decreased or minimally increased 
mortality among patients with giant cell arteritis (GCA) compared with the general 
population.  In a multi-center study from North-America (3), a population-based 
study from Minnesota (6) and a single center from Northern Spain (1), no 
increase in mortality was found. Three studies have found increased mortality 
risks only in the first year after diagnosis (4, 5, 8).  
The histopathology of GCA is characterized by inflammation to a varying degree 
of an affected vessel and hyperplasia of the intima layer of the vessel. 
Sometimes the inflammatory infiltrate contains multinucleated giant cells, from 
which the disease takes its name (9), but are of undetermined significance with 
respect to disease occurrence, clinical presentation and prognosis. There is 
scant information on how histopathology findings are associated with 
complications and outcomes of patients with GCA (10, 11)  and we are not aware 
of studies that have examined how histopathological features seen with temporal 
artery biopsy (TAB) are associated with mortality risks in GCA.  
The objective of this study is to determine the association between GCA and 
cardiovascular- and all-cause mortality. In study B of this thesis, a substantial 
discordance was observed between our classification of GCA-status and the 
original pathology report.  Furthermore, those with GCA that did not have 
histological diagnosis of GCA according to the original pathology report had 
substantially higher risk of incident CHD. Such association could be confounded 
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by histologic features of biopsies that are associated with both diagnostic 
discordance and risk of CHD. Therefore, an added objective to this study was to 
explore how early histological diagnosis, inflammatory intensity and other 
histologic features on TABs affect mortality risks. 
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Methods 
Study Design 
To examine the effect of GCA on mortality, a cohort study design was used, 
where incident mortality of subjects with GCA was compared with all other 
members of the Reykjavik Study cohort.  
Study population 
Data from Reykjavik Study were used. The Reykjavik Study has been described 
(see page 5). Briefly, persons, who were born in 1907–1935 and living in 
Reykjavik, Iceland or in adjacent communities on December 1, 1967, were 
invited to participate.  Subjects came for a study visit in 1967–1996, during which 
information on cardiovascular risk factors was obtained.  Those with GCA at 
baseline were excluded.   
For the analysis on the association of GCA with mortality risk at different periods 
after the occurrence of GCA and for an analysis accounting for the competing 
risk of non-cardiovascular mortality, a cohort design with a matched comparison 
group was used. For each subject with GCA we selected 10 subjects alive and 
free of GCA were selected matched on sex and birth year.  
The analysis of histopathology findings of TABs, was done in the cohort after 
excluding those who had underwent TAB at baseline Overview of the sub-
cohorts of the total RS study cohorts used for the analyses of the association 
between GCA and mortality is provided in Table C.1.   
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 19,360 Participants in RS 
 Primary cohort Matched Cohort Biopsy cohort  
size N=19,241 N=2,156 N=19,196 
Inclusion/ 
exclusion 
107 subjects who died 
before the age of fifty 
and 12 subjects with 
GCA before RS study 
visit excluded 
196 subjects with GCA 
and 1960 matched 
reference subjects 
included 
107 subjects who 
died before the age 
of fifty 
57 subjects who 
underwent TAB 
before an RS study 
visit excluded 
 
Analyses: Baseline data  
and main effects of 
GCA on study 
outcomes 
The effect of GCA on 
study outcomes early 
and late after incident 
GCA.  
 
The effect of GCA on 
cardiovascular mortality 
accounting for the 
competing event of 
non-cardiovascular 
mortality 
The effect of 
findings on TAB on 
study outcomes 
 
 
 
 
Table C1. Three sub-cohorts generated from the parent RS study cohort used for 
assessing mortality risks (RS=Reykjavik Study, N=number of subjects, PY=Person-
years of follow up, GCA=Giant cell arteritis, TAB=Temporal artery biopsy) 
 
Exposure Assessment and pathologic review of temporal arteries 
GCA was defined as diagnostic TAB in any of the three pathologic laboratories in 
Iceland. All TABs obtained from members of the RS cohort were re-examined by 
a single pathologist as previously described (see page 22). For a TAB to be 
considered diagnostic for GCA in the current study, it must have infiltration of 
inflammatory cells to the vessel wall. 
Intima hyperplasia was graded as absent (when almost no tissue was present 
between the lumen and the internal elastic membrane (IEM)), mild, moderate and 
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severe (when the intima layer obliterated the vessel lumen on the pathology 
slide). Calcifications were scored as present if found in at least one section at 
any site of the biopsy. For biopsies considered diagnostic for GCA the 
inflammatory intensity was scored as mild, moderate or severe. For each vessel 
layer (adventitia, media and intima) inflammation was scored as present or 
absent. Extent of inflammation was graded as present in 1, 2 or all 3 layers of the 
temporal artery.  Giant cells were scored as present if at least one giant cell was 
found on any section in any vessel layer. The presence of fibrinoid deposition 
was scored as present or absent.  To explore whether TABs were thought to be 
consistent with GCA at the time they were obtained, the original pathology 
reports were reviewed.  An early histologic diagnosis of GCA was defined as 
when at least one of the following features were described in the original biopsy 
report: i)vasculitis, ii)presence of inflammatory infiltrate in the vessel wall, or iii) 
giant cells. Those with a positive TAB (by our “gold standard” review) were 
further classified as having an original report that was positive vs. an original 
report that was negative. 
  
Covariate assessment 
Information on smoking, BMI, cholesterol, ESR, hypertension and DM was 
obtained as previously described (see pages 21–22) during the baseline RS 
study visit before incident GCA 
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Follow-up and outcome assessment 
All subjects were followed from the time of RS study visit or from the time they 
became 50 years of age, whichever occurred later, until the earlier of the time of 
death or December 31st, 2008.   Cardiovascular mortality was assessed from 
death certificates and non-cardiovascular mortality was mortality from all other 
causes. For the analysis of mortality risks early and later after incident GCA, 
follow-up started at the time when TAB was obtained for each GCA patient and 
its matched reference subjects.  
Statistical analysis 
Since no subject developed GCA before the age of 50 years, person-time of 
follow-up before age 50 was not included in this study. Specifically, for subjects 
with GCA the follow-up started from the date of GCA diagnosis. For subjects who 
did not develop GCA during the follow-up, their follow-up started from the date of 
entry if subjects’ age at entry was older than 50 years old; otherwise their follow-
up time started when they became 50 years old. In addition, subjects with GCA 
contributed person-time to the non-GCA cohort before diagnosis of GCA.  All 
subjects were followed until time of death, or December 31st, 2008, whichever 
occurred first. The incidence rate (IR) was calculated as the number of deaths 
divided by the person-years of follow-up for GCA cohort and non-GCA cohort 
separately. The effect of GCA on study outcomes was expressed as incidence 
rate ratio (IRR) with 95% confidence intervals (CIs).  The effect of TAB feature 
was expressed as the IRR with 95% CI, with those subjects that did not undergo 
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TAB as the reference group. To adjust for potential confounding, standardized 
IRRs were calculated using person-time contributed by GCA patients as weights 
in all analyses. Standardized effect estimates were calculated across strata of 
age and sex.  For analysis of cardiovascular mortality additional standardization 
across cardiovascular risk factors was done as previously described (see page 
25).  In addition, for the outcome of cardiovascular mortality a Cox proportional 
hazards regression and survival analysis accounting for the competing event of 
mortality according to the Fine and Gray method  (12), with death from CVD as 
the outcome variable. As GCA could not be modeled as time-varying predictors 
in the competing risk analysis this was done in the matched cohort analysis.  
SAS 9.2 (SAS institute Cary, NC) was used for calculations.  A SAS macro was 
developed for calculations of standardized rate ratios. The macro was developed 
based on (and tested for errors against Episheet (13) for calculations of 
standardized rate ratios and their confidence interval.  The statistical package 
cmprsk in R was used for calculations subdistribution ratios according to the Fine 
and Gray method (12).   
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Results 
Approximately 70% (19,360) of participants who were originally invited to 
participate in the RS came for a study visit from October 26th, 1967 to April 23rd, 
1996.  Of these, 12 subjects had a TAB diagnostic of GCA before their RS study 
visit, and 107 subjects died before age 50. Therefore, 19,241 subjects were 
included in this analysis.  
Baseline characteristics 
During follow-up, 196 subjects developed incident GCA. The baseline 
characteristics of subjects with GCA and their matched comparison cohort are 
shown in Table C.2.  The mean age at diagnosis of GCA was 73.0 (sd=6.6) and 
138 (70.4%) were women. Distribution of cardiovascular risk factors was similar 
among those with GCA and the comparison subjects.   
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 GCA 
(1,664 PY) 
No GCA 
(444,237PY) 
Women 1,201 (72%) 238,177(54%) 
Age   
 -50 to 60 years  10   (1%) 112,307 (25%) 
 -60 to 70 years 260 (15%) 153,651 (35%) 
 -70 to 80 years 825 (50%) 126,988 (29%) 
 -after 80 years 567 (34%) 51,289 (11%) 
Hypertension  661 (40%) 168,549 (38%) 
Smoking   
  -never 742 (45%) 158,510 (36%) 
  -former 384 (23%) 88,404 (20%) 
  -current smoking 538 (32%) 197,295 (44%) 
Total Cholesterol 6.5   (1.2) 6.5   (1.2) 
 <5.6 377 (23%) 104,126 (23%) 
  5.7-6.3 360 (22%) 109,848 (25%) 
  6.4-7.1 438 (26%) 116,799 (26%) 
  7.2-19 489 (29%) 112,750 (25%) 
DM 56   (3%) 13,235   (3%) 
BMI  
 <18.5 0 5,963   (1%) 
 18.5 – 24.9 971 (58%) 210,941 (47%) 
 25-29.9 530 (32%) 178,902 (40%) 
 ≥30 115   (7%) 46,433 (10%) 
ESR  
 0 - 10 1,055 (60%) 304,247 (68%) 
 11-20 384 (23%) 94,962 (21%) 
 >21 271 (16%) 42,732 (10%) 
Table C.2. Baseline characteristics of the GGA and non-GCA subjects Variables 
expressed with number of person-years (percentage) in each strata (GCA=Giant cell 
arteritis, DM=diabetes mellitus, BMI=body mass index, ESR=erythrocyte sedimentation 
rate).  
 
Follow-up and mortality 
Subjects with GCA (n=196) accumulated 1,664 person-years of follow-up and 
comparison subjects (n=19,048) accumulated 444,237 person-years.  Person-
   92
time of follow-up comprised older years of life for GCA patients; 84% were older 
than age 70, compared with only 40% among the comparison cohort (Table C.3). 
The median follow-up time for GCA cohort and non-GCA cohort was 7.1 (IQR: 
3.5–12.5) and 24.3 (IQR: 17.6-29.8) years respectively. During follow-up, 11,396 
(58.6%) subjects died, 111 deaths occurred among GCA subjects and 11,285 in 
the comparison cohort. 
 
 GCA No GCA   
 Deaths PY IR Deaths PY IR RD IRR 
Women         
50-60 0 8.7 0.0 240 56,269.3 4.3 -4.3 
61-70 4 163.5 24.5 730 81,095.2 9.0 15.5 2.72 (1.02-7.26)
71-80 26 616.2 42.2 1653 69,816.4 23.7 18.5 1.78 (1.21-2.63)
>80 40 412.2 97.0 2549 30,996.6 82.2 14.8 1.18 (0.86-1.61)
Men    
50-60 0 3.8 0.0 450 56,038.0 8.0 -8.0 -- 
61-70 1 8.1 10.3 1247 72,556.4 17.2 -6.9 0.60 (0.08-4.26)
71-80 12 17.1 57.2 2229 57,172.3 39.0 18.2 1.47 (0.83-2.59)
>80 28 51.9 180.5 2187 20,293.0 107.8 72.7 1.67 (1.15-2.43)
Both 
sexes 
   
50-60 0 2.3 0.0 690 112,307.3 6.1 -6.1 -- 
61-70 5 4.9 19.2 1977 153,651.7 12.9 6.3 1.49 (0.62-3.59)
71-80 38 12.1 46.0 3882 126,988.8 30.6 15.4 1.51 (1.09-2.07)
>80 68 43.7 119.9 4736 512,89.7 92.3 27.5 1.3 (1.02-1.65)
Table C.3. Age- and sex- specific incidence of mortality Age- and sex stratified 
number of deaths, person-years, Incidence rate of death expressed as number of 
events/1,000 person-years and the association of GCA with death expressed as IRR 
with 95% confidence intervals in strata of age and sex (GCA=Giant cell arteritis, PY= 
Person-years, IR=incidence rate, RD=risk difference, IRR=incidence rate ratio) 
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Association of GCA with all-cause and cardiovascular mortality 
Table C.3 shows age- and sex- specific incidence rates for mortality among GCA 
and non-GCA cohorts. Subjects with GCA had modestly increased risk for all-
cause mortality; the IRR= 1.45 (95% CI: 1.20–1.75) for all-cause mortality 
standardized across age and sex. Sex-specific IRRs were 1.40 (95% CI: 1.11–
1.77) for women and 1.54 (95% CI 1.13–2.10) for men, respectively.  
GCA was associated with increased cardiovascular mortality (IRR=1.50, 95% CI: 
1.13–1.99); the IRR was lower among women (IRR= 1.19, 95% CI: 0.79–1.78) 
than that among men (IRR=2.01, 95% CI: 1.36–2.98). Age-sex stratified IRs and 
IRRs for cardiovascular mortality among GCA and non-GCA subjects are shown 
in Table C.4. Standardization across strata of cardiovascular risk factors did not 
change the overall estimate much:  IRR=1.46 (95% CI: 1.09–1.96) and further 
standardization across strata of ESR attenuated this effect estimate very slightly, 
with IRR=1.39 (95% CI: 1.03–1.88).  
 Effect of GCA on cardiovascular death from Cox proportional hazards regression 
was HR=1.50 (95% CI 1.07–2.10), adjusting for cardiovascular risk factors but 
not ESR.  
In an analysis for cardiovascular mortality, accounting for the competing event of 
non-cardiovascular mortality, risk ratio of GCA for cardiovascular mortality was 
1.17 (95% CI: 0.85 –1.59) adjusting for cardiovascular risk factors but not ESR.  
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 Cardiovascular Mortality Non-cardiovascular Mortality 
 
GCA 
IR 
No 
GCA 
IR RD 
 
 
IRR 
GCA
IR 
No 
GCA
IR RD 
 
 
IRR 
Women    
50-60 0.0 0.9 -0.9 0.0 3.4 -3.4 
61-70 0.0 2.0 -2.0 24.5 7.0 17.5 3.50 (1.31-9.37)
71-80 11.4 7.8 3.5 1.45 (0.69-3.06) 30.8 15.7 15.1 1.96 (1.25-3.09)
>80 41.2 36.4 4.8 1.13   (0.7-1.83) 55.8 45.7 10.1 1.22 (0.81-1.84)
Men    
50-60 0.0 3.8 -3.8 0.0 4.2 -4.2 
61-70 0.0 8.1 -8.1 10.3 9.0 1.3 1.15 (0.16-8.17)
71-80 47.7 17.1 30.6 2.79   (1.5-5.2) 9.5 21.7 -12.2 0.44 (0.11-1.76)
>80 96.7 51.9 44.8 1.86 (1.12-3.1) 83.8 55.8 28.0 1.50 (0.87-2.60)
Both 
sexes 
   
50-60 0.0 2.3 -2.3 0.0 3.8 -3.8 
61-70 0.0 4.9 -4.9 19.2 7.9 11.3 2.42 (1.01-5.83)
71-80 20.6 12.0 8.6 1.71 (1.06-2.76) 25.4 18.4 7.0 1.38 (0.90-2.12)
>80 56.4 42.5 13.9 1.33 (0.94-1.88) 63.5 49.7 13.8 1.28 (0.92-1.77)
Table C.4. Age- and sex specific incidence of cardiovascular mortality and non-
cardiovascular mortality. IR, absolute RDs and IRRs of cardiovascular and non-
cardiovascular mortality among subjects with GCA and non-GCA in the RS cohort 
(GCA=Giant cell arteritis, IR=incidence rate, IRR=incidence rate ratio) 
 
Association of GCA with mortality risks early and late after diagnosis. 
For the analysis on association of GCA with mortality within strata of early and 
late periods after the diagnosis of GCA, 193 subjects with GCA and 1,875 
matched reference subjects were included.  Of the 193 subjects with GCA, only 9 
died in the first year after TAB with IRR= 1.19 (95% CI: 0.58–2.45) during the first 
year after incident GCA (Table C.5).  
  
   95
Table C.5. Mortality risks early and late after diagnosis of GCA. Associations of 
GCA with all-cause mortality, cardiovascular mortality and non-cardiovascular mortality 
in the first year-, first 5 years after incident GCA and during the total follow-up period. 
Associations are expressed as sex and age-standardized IRRs with 95% CIs 
(GCA=Giant cell arteritis) 
 
TABs and mortality risks  
Of the 19,253 subjects that contributed person-time to the RS study after the age 
of 50, 57 underwent a TAB before their study visit and are excluded from the 
analysis. Therefore, 19,196 subjects were included in the analysis on 
histopathology features of TABs. Six hundred and ninety two subjects underwent 
TAB during the follow-up time. Of them, 496 had negative TAB and the remaining 
196 had GCA.  For 69 (35.7%) of those with GCA, the biopsy was described as 
negative according to the original pathology report. Baseline characteristics and 
primary histologic features of subjects with negative and positive TAB are shown 
in Table C.6.  Compared with those who never underwent TAB, subjects with 
either negative or positive TAB had increased mortality risks, with IRR being 1.83 
(95% CI: 1.64–2.05) and 1.38 (95% CI: 1.15–1.67) respectively. For those with 
positive TAB, this increased risk was driven by the subjects with original 
pathology report negative for GCA (IRR= 2.02, 95% CI: 1.52–2.69); but those 
 1 year after GCA 5 years after GCA Total follow-up
All-Cause Mortality 1.25 (0.66-2.36) 1.49 (1.08-2.05) 1.39 (1.11-1.66)
Cardiovascular Mortality 0.75 (0.23-2.49) 1.51 (0.93-2.45) 1.56 (1.16-2.09)
Non-cardiovascular Mortality 1.68 (0.78-3.59) 1.49 (0.98-2.28) 1.28 (0.99-1.67)
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with positive TAB and early histologic diagnosis of GCA had little increased 
mortality (IRR= 1.09, 95% CI: 0.84–1.41). Similar results were also observed for 
cardiovascular mortality (Table C.7). 
 
 No 
 TAB  
(n=18,498) 
Negative 
TAB 
(n=501) 
Positive  
TAB (GCA) 
(n=196) 
   Originally 
reported 
negative 
(n=71) 
Originally 
reported 
positive 
(n=125) 
Female 234,659 (53%) 3,225 (75%) 322 (71%) 878 (73%)
Age*  
50-60 112,129 (26%) 143   (3%) 0   (0%) 10   (1%)
61-70 152,725 (35%) 840 (20%) 44 (10%) 217 (18%)
71-80 124,792 (28%) 2,034 (47%) 210 (46%) 616 (51%)
>80 49,825 (11%) 1,267 (30%) 202 (44%) 366 (30%)
Intima thickening -  
-none 519 (12%) 0   (0%) 18   (2%)
-mild 2,421 (57%) 33   (8%) 16   (1%)
-moderate 1,220 (29%) 275 (63%) 408 (34%)
-severe 73   (2%) 132 (30%) 759 (63%)
Calcification 237   (6%) 46 (10%) 148 (13%)
Inflammatory 
intensity 
 
-mild 311 (68%) 123 (10%)
-moderate 97 (21%) 486 (40%)
-severe 47 (10%) 600 (50%)
Giant Cells 166 (37%) 984 (81%)
Table C.6. Baseline characteristics and primary histologic findings among 
subjects who did not undergo TAB, subjects with negative TABs, and subjects 
with positive TABs further stratified according to whether TAB was originally 
reported negative or positive. Characteristics expressed as number of person-years 
(percentage) in each stratum (TAB=Temporal artery biopsy, GCA=Giant cell arteritis, 
BMI=body mass index, ESR=erythrocyte sedimentation rate, IQR=interquartile range) 
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 Mortality CVD Mortality 
No Temporal artery biopsy 1 (ref) 1 (ref)
Biopsy results 
Negative 1.83(1.64-2.05) 2.02(1.72-2.38)
Positive   
-- originally reported negative  2.18(1.65-2.90) 2.34(1.57-3.49)
-- originally reported positive 1.10(0.85-1.42) 1.06(0.71-1.58)
Inflammation* 
Intensity 
Mild  2.15(1.60-2.88) 2.13(1.36-3.32)
Moderate  1.26(0.85-1.85) 1.38(0.78-2.43)
Severe  1.13(0.81-1.57) 1.07(0.65-1.78)
Adventitia Inflammation 
absent 1.94(1.14-3.32) 1.94(1.14-3.32)
present 1.33(0.95-1.86) 1.33(0.95-1.86)
Media Inflammation 
absent 2.30(1.57-3.37) 2.43(1.37-4.29)
present 1.25(1.01-1.56) 1.26(0.91-1.76)
Intima Inflammation 
absent 2.53(0.62-10.29) 1.88(0.47-7.53)
present 1.39(1.15-1.68) 1.40(1.05-1.86)
Extent 
1 layer 2.49(1.66-3.72) 2.11(1.08-4.15)
2 layers 1.74(0.93-3.27) 1.66(0.81-3.39)
3 layers 1.24(0.98-1.56) 1.24(0.87-1.77)
Intima hyperplasia 
   Negative biopsies 
   -- none 1.23(0.73-2.07) 1.22(0.53-2.82)
   -- mild 1.71(1.47-1.98) 1.89(1.53-2.35)
   -- moderate 2.24(1.86-2.69) 2.61(2.00-3.40)
-- severe 2.00(0.85-4.72) 1.13(0.16-8.06)
Positive biopsies 
-- none 1.72(0.24-12.18) -
-- mild 0.54(0.17-1.69) 0.64(0.13-3.09)
-- moderate 1.57(1.20-2.06) 1.60(1.07-2.40)
-- severe 1.32(1.00-1.74) 1.34(0.88-2.05)
Giant cells* 
absent 1.93(1.45-2.58) 1.89(1.24-2.89)
present 1.19(0.92-1.54) 1.23(0.83-1.80)
Fibrinoid deposition* 
absent 1.48(1.20-1.82) 1.45(1.05-2.00)
present 1.16(0.73-1.84) 1.24(0.63-2.45)
Eosinophils* 
absent 1.41(1.15-1.72) 1.41(1.03-1.91)
present 1.07(0.31-3.68) -
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 Mortality CVD Mortality 
Calcification   
Negative biopsies   
-- absent 1.74(1.55-1.96) 1.91(1.61-2.26)
-- present 3.64(2.45-5.41) 5.45(3.14-9.45)
Positive biopsies 
-- absent 1.38(1.12-1.69) 1.48(1.09-2.02)
-- present 2.06(1.20-3.53) 1.35(0.54-3.38)
Table C.7. The association of temporal artery biopsies and histologic features with 
all-cause mortality and cardiovascular mortality. The association of each level of 
biopsy finding/histologic feature with study outcomes is expressed as IRR with 95% CI 
with those that never underwent TAB as the referent group (CHD=Coronary heart 
disease, CVD=cardiovascular disease, IRR=incidence rate ratio, CI=confidence interval).  
* Only assessed on positive temporal artery biopsies 
 
Histopathology and mortality risks 
TABs that were originally reported positive for GCA where characterized by more 
severe intima hyperplasia (thickening), more intense infiltration of inflammatory 
cells and more frequently observed giant cells than those TABs that were 
originally reported negative but found positive for the purpose of this study (Table 
C.6).  
 
Among those with negative TABs, intima hyperplasia and calcifications were 
markedly associated with mortality (Table C.7).  Among subjects with GCA, mild 
inflammatory intensity was associated with higher mortality risks than those with 
moderate and severe inflammatory intensity, IRR=2.15 (95% CI: 1.60–2.88), 
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IRR=1.26 (95% CI: 0.85–1.85) and IRR= 1.13 (95% CI: 0.81–1.57), respectively. 
An inverse association between inflammatory intensity was also observed with 
cardiovascular mortality. These inverse associations were not driven by those 
with GCA who originally had TAB reported as negative, as analysis restricted to 
those with early histologic diagnosis of GCA, showed inverse associations 
between inflammatory intensity and mortality risks (Table C.8).  
In the analysis of association of histopathology features with mortality no 
substantial effect measure modification between men and women was observed 
(results not shown).  
 Mortality CVD Mortality 
No Temporal artery biopsy 1 (ref) 1 (ref) 
Biopsies originally reported negative 
Inflammatory intensity 
-mild  2.65(1.81-3.87) 2.34(1.39-3.95)
-moderate 1.46(0.58-3.68) 2.60(0.85-8.01)
-severe 2.06(0.87-4.90) 3.69(1.30-10.48)
Biopsies originally reported positive 
(early histologic diagnosis of GCA) 
Inflammatory intensity 
-mild  1.43(0.74-2.77) 1.86(0.76-4.51)
-moderate  1.23(0.80-1.90) 1.19(0.60-2.34)
-severe  0.98(0.68-1.43) 0.80(0.43-1.49)
Table C.8. The association of levels of inflammatory intensity on mortality and 
cardiovascular mortality among subjects with GCA stratified according to whether 
the diagnosis of GCA was made by the original biopsy report. The association of 
each level of inflammatory intensity with study outcomes is expressed as age- and sex 
standardized IRRs with 95% CI (CVD=cardiovascular disease, CHD=Coronary heart 
disease)  
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Discussion 
 
This study finds a modest association between GCA and all-cause mortality. This 
finding is mainly driven by subjects who had biopsies were classified as having 
GCA for the purpose of this study but were not diagnosed with GCA on the basis 
of the original pathology report.  On the other hand, subjects with an early 
histologic diagnosis of GCA have mortality risks similar to those of the general 
population.  This study suggests an inverse relationship between inflammatory 
changes on TABs and mortality risks.   
This study has important strengths. Detailed pathologic examination was done 
according to a predefined protocol on all TABs obtained in a well-defined 
population-based cohort.  Identifying a group of patients with GCA, who was not 
diagnosed with GCA at the time of TAB, could provide a valuable insight to the 
natural history of GCA pertaining to mortality risks.  
This study also has several limitations. No data on clinical presentation and 
treatment are available; thus we have no information of the clinical diagnosis by 
the treating physician who might have made the diagnosis of GCA based on 
clinical findings. However, that practice appears to be rare in Iceland (14).  Data 
on ESR and cardiovascular risk factors were obtained long before TABs were 
performed.  
In contrast to some other studies (4, 5, 8), we did not find an increased mortality 
risks in the first year after incident GCA, but the IRRs are too imprecise to draw 
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firm conclusions. It is not surprising that a negative TAB is associated with 
increased mortality risks as those who undergo TAB are often patients with some 
undefined illness requiring hospitalization. Our study is consistent with most 
previous studies reporting no or minimal increased mortality risks among subject 
diagnosed with GCA (1-7) compared with the general population. The finding of 
substantial effect-measure modification based on whether diagnosis of GCA was 
made on the original pathology report is intriguing. There are at least four 
scenarios that could explain this finding: First, it is likely that several of the 
patients classified as having GCA for the purpose of this study with no mention of 
GCA on the original pathology report and never were clinically diagnosed with 
GCA later; thus, these subjects may have never received treatment with high 
dose glucocorticoids. It is possible that anti-inflammatory treatment for GCA that 
is mainly targeted towards symptoms and to prevent ocular complications also 
has benefits with respect to mortality risks. Second, it is possible that our findings 
are driven by misclassification of GCA status, that most of the 71 subjects that 
we classify as having GCA but were not diagnosed with GCA according to the 
original pathology report, are indeed free of GCA; thus they could have 
experienced the same elevated risk for the study outcomes as those with truly 
negative biopsies. Third, our data suggest that those with less inflammatory 
intensity on TAB are at higher all-cause mortality- and cardiovascular mortality 
risks. This counterintuitive finding (see below) could partially explain why those 
with GCA but without early histologic diagnosis have higher mortality risks. 
   102
Fourth, it is possible that our findings are driven by chance. While an inverse 
association between inflammatory intensity and several study outcomes are 
consistently found, our estimates are driven by few events among those with 
GCA and are surrounded by wide confidence intervals.  
The finding of an inverse association between inflammatory intensity on TAB and 
study outcomes was unexpected. We are not aware of any published studies 
describing the association between histologic findings and CHD and/or mortality.  
There was a paucity of data on the association between histologic features of 
TABs, clinical symptoms and outcomes in GCA (10, 15-17). One study has 
reported that inflammatory intensity is not associated with visual loss among 
patients with GCA (10). Two studies have found that intima hyperplasia was 
associated with cranial ischemic complications (10, 11). In this study, no clear 
association was found between intima hyperplasia and study outcomes among 
subjects with GCA, although there was a clear association of intima hyperplasia 
with CHD and mortality among those with truly negative biopsies. It is evident 
that the inverse relationship between inflammatory intensity and mortality risks 
observed in this study must be produced by a strong confounder. One such 
confounder could be duration of disease:  specifically, subjects with low level of 
inflammation have had longer disease duration that had gone undetected for 
longer periods of time than those with intensive inflammatory infiltration. 
Susceptibility to treatment is another potential confounder of this association that 
is, patients with less intense inflammation might be more resistant to treatment 
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than those with intense vascular inflammation.  
Sub-distribution risk ratio for the association of GCA with cardiovascular mortality 
accounting for the competing event of other causes of mortality obtained from the 
Fine and Gray model was substantially lower than the IRR and cause-specific 
hazards ratio obtained from the traditional Cox proportional hazards model. The 
underlying distribution for Fine and Gray model is the cumulative incidence 
function but the underlying distribution for the Cox model is the hazard function. 
In this older age population with long follow-up time over 50% of subjects 
experienced the competing event (mortality).  With long follow-up times, 
cumulative incidence of mortality approaches 1. Those modeling differences may 
be the explanation for the discrepant results between the two modeling 
approaches. In an analysis of the association of GCA with cardiovascular 
mortality restricted to the first five years, cause specific hazards ratio and sub-
distribution risk ratio gave similar numerical estimates (HR=1.81 and sub-
distribution risk ratio 1.76). A recent study originating from the RS cohort on 
cumulative incidence of bony fractures found that estimates adjusted for 
competing event of death only deviated from unadjusted estimates after long 
periods of follow-up (18).  
In summary, patients diagnosed with GCA have similar cardiovascular- and all-
cause mortality risks as those observed for the general population. However, 
subjects without early histologic diagnosis of GCA and those with very mild 
inflammatory changes on TAB have substantially increased mortality risks. 
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Appendix A: SAS macro for calculations of standardized incidence ratios 
/*  
 
The levelstrat macro provides standardized incidence rate 
ratios 
with 95% CI.  across age and across level of variables 
specified by the user.  
the data set must contain the following variables 
 
1. py50to60: number of person-years contributed by the 
subject from  
the age of 50 to 60.  
2. py60to70: number of person-years contributed by the 
subject from  
the age of 60 to 70.  
3. py70to80: number of person-years contributed by the 
subject from  
the age of 70 to 80.  
4. pypost80: number of person-years contributed by the 
subject from  
after the age of 80.  
 
 
The following variables need to be specified when the macro 
is executed 
 
DATA= name of data set 
OUTCOME=outcome variable that takes the level of 0 if 
outcome did not occur,  
takes the level of 1 if outcome occurred between the age of 
50 to 60, 2 if  
the outcome occurred between the age of 60 to 70, 3 if the 
outcome occurred 
between the age of 70 to 80 and 4 if the outcome occurred 
after the age of 80.  
MAIN=Exposure variable of primary interest.  
LEVEL=The number of possible values for the MAIN variable 
(2 for dichotomous) 
weight will be based on person-type contributed by sum of 
person-years with  
main=1 in each strata.  
STRATLIST=Up to 10 variables across which estimates will be 
standardized.  
   107
RESTRICTVAR and RESTRICTVAL. for calculation of subset of 
the data for example if in 
a restricted analysis to man, RESTICTVAR is specified as 
man and then 
RESTRICTVAL=1. RESTRICTVAR and RESTTRICTVAL should be left 
blank if  
all observations are to be used.  
 
*/ 
 
%macro 
levelstrat(data,outcome,main,level,stratlist,restrictvar,re
strictval); 
    
data limdata; 
set &data; 
if &restrictvar=&restrictval; 
run; 
 
%let agelist=py50to60 py60to70 py70to80 pypost80; 
%let a=%length(&stratlist); 
%put &a; 
 
%do j=1 %to 4; 
  
 %let agef = %qscan(&agelist, &j); 
 %let age&j=%upcase(&agef); 
 
%if &a^=0 %then %do; 
 %do count=1 %to 10; 
  %let stratf = %qscan(&stratlist, &count); 
  %let strat&count=%upcase(&stratf); 
  %if (&stratf ne) %then %let numstrat=&count; 
 %end; 
%end; 
 
 %let freqset= macrotrikk; 
 %let sortset= macrotrikk; 
 %let type=111; 
 %let commaset=marcrotrikk,agegroup; 
 
%if &a^=0 %then %do; 
 %do i = 1 %to &numstrat; 
  %let curstrat = &&strat&i; 
  %let freqset= &freqset * &curstrat; 
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  %let sortset= &main &sortset descending 
&curstrat; 
  %let commaset=&commaset , &curstrat; 
  %let type=&type.1; 
 %end; 
%end; 
 
 ods output summary=sjit; 
 proc means data=limdata sum; 
 *where bxstatus3 ne 4; 
 class macrotrikk &stratlist &main; 
 var &&age&j; 
 run; 
 ods output close; 
 
 ods output summary=sjit2; 
 proc means data=limdata sum; 
 class macrotrikk &stratlist &main; 
 var &&age&j; 
 run; 
 ods output close; 
 
 proc sort data=sjit; 
 by &stratlist &main; 
 run; 
 
 proc sort data=sjit2; 
 by &stratlist &main; 
 run; 
 
 ods output  CrossTabFreqs=prestuff;  
 proc freq data=limdata; 
 *where bxstatus3 ne 4; 
 tables &freqset * &main * &outcome/nocol norow 
nopercent; 
 run; 
 ods output close; 
 
 data stuff; 
 set prestuff; 
 if &outcome=&j and _type_="&type"; 
 run; 
 
 proc sort data=stuff; 
 by &stratlist macrotrikk; 
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 run; 
 
 data mix&j; 
 merge sjit stuff; 
 by &stratlist macrotrikk; 
 agegroup=&j; 
 fuyears=&&age&j.._Sum; 
 run; 
 
 data wprep&j; 
 set sjit2; 
 agegroup=&j; 
 weightyears=&&age&j.._Sum; 
 run; 
%end; 
 
 
data catprep; 
set mix1 mix2 mix3 mix4; 
run; 
 
data weightprep; 
set wprep1 wprep2 wprep3 wprep4; 
if &main=1; 
run; 
 
proc sort data=catprep; 
by agegroup &stratlist &main; 
run; 
 
proc sort data=weightprep; 
by agegroup &stratlist &main; 
run; 
 
data combined; 
merge weightprep catprep; 
by agegroup &stratlist; 
run; 
 
proc sort data=combined; 
by macrotrikk agegroup &main ; 
run; 
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ods rtf file="C:\Users\Gunnar\Documents\GCA\study 
2\augustremake\data\&main.Stratified.rtf"; 
proc print data=combined; 
var macrotrikk agegroup &stratlist &main frequency fuyears 
weightyears; 
run;  
ods rtf close; 
 
data combined2; 
set combined; 
strats=cats(&commaset); 
exposed=&main; 
keep strats macrotrikk agegroup &main frequency fuyears 
weightyears; 
run; 
 
proc sort data=combined2; 
by strats descending &main; 
run; 
 
data combined3; 
set combined2; 
by strats descending &main; 
 retain fu_exposed1-fu_exposed&level freq_exposed1-
freq_exposed&level; 
 
 
%do k=1 %to &level; 
 
 if &level=2 then do; 
  if &main=2 then do; 
   fu_exposed2=fuyears; 
   freq_exposed2=frequency; 
  end; 
  if &main=1 then do; 
    fu_exposed1=fuyears; 
   freq_exposed1=frequency; 
  end; 
 end; 
 else if &main=&k then do; 
  fu_exposed&k=fuyears; 
  freq_exposed&k=frequency; 
 end; 
%end; 
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weight=weightyears; 
keep macrotrikk &main fu_exposed1-fu_exposed&level 
freq_exposed1-freq_exposed&level fuyears weight; 
if last.strats then output; 
run; 
 
data combined4; 
set combined3; 
%do m=1 %to &level; 
 if fu_exposed&m ne 0 then 
rate_exposed&m=freq_exposed&m/fu_exposed&m; else 
rate_exposed&m=0; 
 wR_exposed&m=rate_exposed&m*weight; 
 if fu_exposed&m ne 0 then 
WWvar_exposed&m=weight**2*rate_exposed&m/fu_exposed&m; else 
WWvar_exposed&m=0; 
%end; 
run; 
 
ods output summary=sumstoff; 
proc means data=combined4 sum; 
class macrotrikk; 
var  
rate_exposed1-rate_exposed&level 
wR_exposed1-wR_exposed&level 
WWvar_exposed1-WWvar_exposed&level 
weight; 
run; 
ods output close; 
 
data sumstoff2; 
set sumstoff; 
keep macrotrikk  
%do n=1 %to &level; 
 rate_exposed&n._sum  wR_exposed&n._sum  
WWvar_exposed&n._sum  
%end; 
weight_sum 
; 
run; 
 
data sumstoff3; 
set sumstoff2; 
%do x=1 %to &level; 
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 stdrate_exposed&x=wR_exposed&x._sum/weight_sum; 
%end; 
%do y=2 %to &level; 
 stdIRR&y=stdrate_exposed&y/stdrate_exposed1; 
 logstdERR&y=sqrt((WWvar_exposed1_sum/wR_exposed1_sum**
2)+(WWvar_exposed&y._sum/wR_exposed&y._sum**2)); 
 
 stdIRR&y.up=exp(log(stdIRR&y)+1.96*logstdERR&y); 
 stdIRR&y.lo=exp(log(stdIRR&y)-1.96*logstdERR&y); 
%end; 
run; 
 
data sumstoff4; 
set sumstoff3; 
%do z=2 %to &level;  
keep macrotrikk stdIRR&z stdIRR&z.lo stdIRR&z.up;  
%end;  
run; 
 
proc print data=sumstoff4; 
run; 
 
data sumstoff5; 
set sumstoff4; 
%do z=2 %to &level;  
 IRR&z=round(stdIRR&z, .01); 
 LCL&z=round(stdIRR&z.lo, .01); 
 UCL&z=round(stdIRR&z.up, .01); 
 charIRR&z=put(IRR&z, 7.2); 
 charLCL&z=put(LCL&z, 7.2); 
 charUCL&z=put(UCL&z, 7.2); 
 estimate&z=cats(charIRR&z,"   (",charLCL&z,"-
",charUCL&z,")"); 
%end; 
run; 
 
proc print data=sumstoff5; 
run; 
 
data sumstoff6; 
set sumstoff5; 
%do z=2 %to &level; 
keep macrotrikk estimate&z ;  
%end; 
run; 
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proc print data=sumstoff6; 
run; 
 
data sumstoff7; 
set sumstoff6; 
estimate1=" 1 (ref)"; 
array estimates[&level] estimate1-estimate&level; 
if macrotrikk=0 then do i=1 to &level; 
   sex="women"; 
   level=i; 
   estimate=estimates[i]; 
   output; 
end; 
if macrotrikk=1 then do j=1 to &level; 
   sex="macrotrikk"; 
   level=j; 
   estimate=estimates[j]; 
   output; 
end; 
keep sex level estimate; 
run; 
 
ods rtf file="C:\Users\Gunnar\Documents\GCA\study 
2\augustremake\data\&outcome.&main..rtf"; 
proc print data=sumstoff7; 
title "Effect of &main standardized according to age 
&stratlist"; 
run; 
ods rtf close; 
 
 
%mend levelstrat; 
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Appendix B: SAS macro for evaluation for cyclical incidence 
%macro circular(inclist); 
 
%do count=1 %to 100; 
 %let incf= %qscan(&inclist, &count); 
 %let incf&count=%upcase(&incf); 
 %if (&incf ne) %then %let numincidence=&count; 
%end; 
 
 
data one; 
array counts [&numincidence] inc1-inc&numincidence 
(&inclist); 
N=sum(of counts[*]); 
k=&numincidence; 
pi=3.14156592; 
do i=1 to k; 
 theta=(2*pi*i)/k; 
 par1=1/k*counts[i]*sin(theta); 
 par2=1/k*counts[i]*cos(theta); 
 output; 
end; 
keep N k par1 par2; 
run; 
 
proc sort data=one;by k;run; 
 
data two; 
set one; 
by k; 
retain sumpar1; 
if first.k then sumpar1=par1; 
else sumpar1=par1+sumpar1; 
retain sumpar2; 
if first.k then sumpar2=par2; 
else sumpar2=par2+sumpar2; 
if last.k then output; 
keep sumpar1 sumpar2 k N; 
run; 
 
data three; 
set two; 
D=sqrt(sumpar1**2 + sumpar2**2); 
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alpha=2*k*D/N; 
R=(1+alpha)/(1-alpha); 
VARalpha=2/N; 
SElnR=(2*sqrt(VARalpha)/((1+alpha)*(1-alpha))); 
Rlower=exp(log(R)-1.96*SElnR); 
Rupper=exp(log(R)+1.96*SElnR); 
run; 
 
proc print data=three; 
run; 
 
%mend circular; 
 
 
%circular(18 21 36 37 32 25 22) 
 
/* 
18 is the total number of subjects with gca in 1980, 1987, 
1994 and 2001 
21 is the total number of subjects with gca in 1981, 1988, 
1995 and 2002 
36 is the total number of subjects with gca in 1982, 1989, 
1996 and 2003 
37 is the total number of subjects with gca in 1983, 1990, 
1997 and 2004 
32 is the total number of subjects with gca in 1984, 1991, 
1998 and 2005 
25 is the total number of subjects with gca in 1985, 1992, 
1999 and 2006 
22 is the total number of subjects with gca in 1986, 1993, 
2000 and 2007 
*/ 
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